Compounds with kinase inhibitory activity
Novel FLT3 kinase inhibitors, characterized by specific chemical structures, address the limitations of current drugs by effectively inhibiting FLT3 kinase activity to treat diseases like acute myeloid leukemia with reduced toxicity.
Patent Information
- Application Number
- JP2023504794
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-02-08
- Filing Date
- 2021-07-22
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2041-07-22
AI Technical Summary
Current therapeutic drugs for treating diseases associated with FLT3 activity or expression, such as acute myeloid leukemia, suffer from unclear therapeutic effects and significant toxic side effects, highlighting the need for new FLT3 kinase inhibitors.
Development of novel FLT3 kinase inhibitors, represented by compounds of a specific chemical formula, which include heteroaromatic rings and various substituents, designed to target FLT3 kinase activity and regulate its aberrant function.
The new FLT3 kinase inhibitors effectively inhibit FLT3 kinase activity, offering potential therapeutic benefits with reduced toxicity, thereby addressing the limitations of existing drugs in treating diseases like acute myeloid leukemia.
Smart Images

Figure 0007584623000001 
Figure 0007584623000002 
Figure 0007584623000003
Abstract
Description
[Technical field]
[0001] The present invention relates to the fields of medicinal chemistry and medicine, and in particular to FLT3 compounds, methods for their preparation and use for treating diseases associated with abnormal FLT3 activity or expression levels, such as acute myeloid leukemia. [Background technology]
[0002] The development of malignant tumors is a complex process, and traditional therapeutic drugs are mainly divided into several types, such as alkylating agents, antimetabolites, natural products, and antibiotics. The disadvantages of these several types of drugs are that the therapeutic effect is unclear and the side effects of toxicity are large. Currently, small molecule kinase inhibitors are a field that has attracted attention as a potential cancer treatment. Protein kinases are catalysts and play important roles in almost all aspects of cell biology and biochemistry. These enzymes generate signaling modules that regulate cell cycle progression, proliferation, programmed cell death (apoptosis), cytoskeleton function, motility, differentiation, development, transcription, and translation. The roles of protein kinases are numerous, and careful regulation of them is important because abnormal activity can cause cancer, cardiovascular disease, inflammation, and neurological disorders. Dysregulation, overexpression, and mutation of protein kinases play causative roles in the pathogenic mechanisms of human diseases, making these enzymes attractive drug targets. Growth factor receptors with protein tyrosine kinase (PTKs) activity are known as receptor tyrosine kinases. Protein receptor tyrosine kinases are tightly regulated enzymes, and aberrant activation of various members of the family is one of the hallmarks of cancer. Receptors such as FLT3, KIT, FMS, and platelet-derived growth factor receptor (PDGFR) belong to the receptor tyrosine kinase family, and these receptors play important roles in regulating hematopoiesis.
[0003] FLT3 (FMS-like tyrosine kinase-3) is a specific cytokine receptor expressed in hematopoietic stem cells and has the regulatory function of survival and growth of hematopoietic stem cells and progenitor cells, maturation of dendritic cells, and homeostasis of regulatory T cells. Approximately 30% of acute myeloid leukemia (AML) patients have the phenomenon of FLT3 gene mutation, mainly including FLT3 internal tandem duplication (FLT3-ITD) and point mutation in FLT3 tyrosine kinase domain (FLT3-TKD). FLT3-ITD mutation is known to lead to constitutive and ligand-independent activation of tyrosine kinase function and poor prognosis of patient survival, accounting for approximately 25% of AML patients, and FLT3-TKD accounts for approximately 5% to 10%. FLT3 can dimerize and undergo autophosphorylation upon ligand binding, thus initiating multiple intracellular signaling programs. In vitro experiments show that FLT3 mutations can promote cell proliferation and inhibit cell apoptosis through MAPK, PI3K / AKT / Mtor and STAT5 downstream signaling pathways. The high incidence and poor prognosis of FLT3 mutations suggest that they can be used as an important target for AML treatment.
[0004] In summary, there is an urgent need in the art to develop new FLT3 kinase inhibitors. Summary of the Invention [Problem to be solved by the invention]
[0005] An object of the present invention is to provide a new FLT3 kinase inhibitor. [Means for solving the problem]
[0006] A first aspect of the present invention provides a compound as shown in formula I, or a pharma- ceutically acceptable salt or deuterated form thereof: [ka] Where: [ka] the ring is an aza 5-6 membered heteroaromatic ring; [ka] is a 5- or 6-membered aromatic ring or heteroaromatic ring, [ka] Ring and [ka] the rings taken together form a 9- to 10-membered heteroaromatic ring; Ra is H, halogen, substituted or unsubstituted C 1 -C 6 Alkyl group, substituted or unsubstituted C 2 -C 6 Alkenyl group, substituted or unsubstituted C 2 -C 6 Alkynyl group, substituted or unsubstituted C 3 -C 8 Carbocycles (including saturated or partially unsaturated), substituted or unsubstituted 5-9 membered heteroaromatic rings (including monocyclic or fused rings) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted 3-8 membered heterocycles containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen (which are saturated or partially unsaturated heterocycles, preferably substituted or unsubstituted C 3 -C 6 a substituted or unsubstituted 3-6 membered heterocycle containing 1-3 heteroatoms selected from a cycloalkyl group, oxygen, sulfur and nitrogen, or a substituted or unsubstituted -[L] m —H groups, wherein each L is independently selected from the group consisting of —CH 2 -, -O-, -NH- or -S-; m is selected from the group consisting of 1, 2, 3, 4, 5 or 6; U is a chemical bond or -O-, -CHR-, a carbonyl group, S, -NH-, -NHC(O)-, -NHS(O) 2 -, -NHC(O)NH-, -NHC(S)NH-, -COO-, -OS(O) 2 - selected from the group consisting of Rc is H, substituted or unsubstituted C 1 -C 6 Alkyl groups, substituted or unsubstituted C 3 -C 8 Carbocycles (including saturated or partially unsaturated), substituted or unsubstituted 3-8 membered heterocycles (saturated or partially unsaturated, including monocyclic, fused, bridged or spirocyclic rings) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted C 6 -C 10 a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from an aryl group, oxygen, sulfur and nitrogen, or a substituted or unsubstituted -[L] m —H groups, wherein each L is independently selected from the group consisting of —CH 2 -, -O-, -NH- or -S-; Re is halogen, -NHR, -OR, substituted or unsubstituted C 1 -C 6 Alkyl groups, substituted or unsubstituted C 1 -C 6 Alkyl-NH-, substituted or unsubstituted C 1 -C 6 Alkoxy group, substituted or unsubstituted C 3 -C 8 Carbocyclic ring (including saturated or partially unsaturated), or substituted or unsubstituted -[L] m —H groups, wherein each L is independently selected from the group consisting of —CH 2 -, -O-, -NH- or -S-; W is H, -NHR, -OR, halogen, substituted or unsubstituted C1 -C 6 Alkyl groups, substituted or unsubstituted C 1 -C 6 Alkoxy groups, substituted or unsubstituted C 2 -C 6 Alkenyl groups, substituted or unsubstituted C 2 -C 6 Alkynyl groups, substituted or unsubstituted C 3 -C 8 Carbocyclic rings (including saturated or partially unsaturated), substituted or unsubstituted C 6 -C 10 aryl groups, substituted or unsubstituted 4-15 membered heterocycles (saturated or partially unsaturated rings including monocyclic, fused, bridged or spirocyclic rings) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen; substituted or unsubstituted 5-12 membered heteroaromatic rings (including monocyclic or fused rings) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen; substituted or unsubstituted -C 1 -C 6 Alkyl-phenyl group, substituted or unsubstituted C 3 -C 12 Cycloalkyl groups (including monocyclic, fused, bridged or spirocyclic groups), substituted or unsubstituted C 2 -C 10 Acyl group, substituted or unsubstituted C 2 -C 10 Ester group, substituted or unsubstituted C 6 -C 10 Aryloxy group, substituted or unsubstituted C 1 -C 6 an amide group; The W group is substituted with at least one group having the structure -MA, where M is a chemical bond, or -CHR-, a carbonyl group, S, O, -NH-, -NHC(O)-, -NHS(O), 2 -, -NHC(O)NH-, -NHC(S)NH-, -COO-, -OS(O) 2 - selected from the group consisting of The A is H, a halogen, a cyano group, an amino group, a nitro group, a hydroxyl group, a mercapto group, an aldehyde group, a carboxyl group, a sulfonyl group, a substituted or unsubstituted C 1 -C 6 Alkyl groups, substituted or unsubstituted C 1 -C 6 Alkoxy groups, substituted or unsubstituted C 6 -C 10 aryl groups, substituted or unsubstituted 4-12 membered heterocycles (including monocyclic, fused polycyclic, bridged or spirocycles) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen; substituted or unsubstituted 5-12 membered heteroaromatic rings (including monocyclic or fused rings) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen; substituted or unsubstituted -C 1 -C 6 Alkyl-phenyl groups, substituted or unsubstituted C 3 -C 12 Cycloalkyl groups, substituted or unsubstituted C 2 -C 10 Acyl groups, substituted or unsubstituted C 2 -C 10 Ester group, substituted or unsubstituted C 6 -C 10 Aryloxy groups, substituted or unsubstituted C 1 -C 6 Amide group, substituted or unsubstituted C 1 -C 4 Alkyl-S(O) 2 -, substituted or unsubstituted C 1 -C 4 alkyl-SO-; In the A group, the substitution refers to substitution with one or more groups selected from group B, and group B is H, halogen, =O, a cyano group, an amino group, a nitro group, a hydroxyl group, a mercapto group, an aldehyde group, a carboxyl group, a sulfonyl group, a substituted or unsubstituted C1 -C 6 Alkyl groups, substituted or unsubstituted C 1 -C 6 Alkoxy groups, substituted or unsubstituted C 6 -C 10 aryl groups, substituted or unsubstituted 3-12 membered (preferably 5-7 membered) heterocycles containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted 5-12 membered heteroaromatic rings containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted -C 1 -C 6 Alkyl-phenyl groups, substituted or unsubstituted C 3 -C 12 Cycloalkyl groups, substituted or unsubstituted C 2 -C 10 Acyl groups, substituted or unsubstituted C 2 -C 10 Ester group, substituted or unsubstituted C 6 -C 10 Aryloxy groups, substituted or unsubstituted C 1 -C 6 Amide group, substituted or unsubstituted C 1 -C 4 Alkyl-S(O) 2 -, substituted or unsubstituted C 1 -C 4 alkyl-SO-, wherein in said Group B, said substitution refers to substitution with one or more R groups; R is H, halogen, cyano, amino, nitro, hydroxyl, mercapto, aldehyde, carboxyl, sulfonyl, substituted or unsubstituted C 1 -C 6 Alkyl groups, substituted or unsubstituted C 1 -C 6 Alkoxy groups, substituted or unsubstituted C 6 -C 10 a substituted or unsubstituted 5-7 membered heterocycle containing 1-3 heteroatoms selected from aryl groups, oxygen, sulfur and nitrogen; a substituted or unsubstituted -C 1 -C 6 Alkyl-phenyl groups, substituted or unsubstituted C 3 -C12 Cycloalkyl groups, substituted or unsubstituted C 2 -C 10 Acyl groups, substituted or unsubstituted C 2 -C 10 Ester group, substituted or unsubstituted C 6 -C 10 Aryloxy groups, substituted or unsubstituted C 1 -C 6 Amide group, substituted or unsubstituted C 1 -C 4 Alkyl-S(O) 2 -, substituted or unsubstituted C 1 -C 4 is a group selected from the group consisting of alkyl-SO-, Unless otherwise specified, in each of the above formulas, the substitution means that the hydrogen atom of the corresponding group is replaced with deuterium, tritium, halogen, hydroxyl group, carboxyl group, mercapto group, benzyl group, C 1 -C 12 Alkoxycarbonyl group, C 1 -C 6 Aldehyde group, amino group, C 1 -C 6 Amido, nitro, cyano, unsubstituted or halogenated C 1 -C 6 Alkyl groups, unsubstituted or halogenated C 3 -C 8 Cycloalkyl groups, C 2 -C 10 Alkenyl group, C 1 -C 6 Alkoxy group, C 1 -C 6 Alkyl-amine group, C 6 -C 10 Aryl groups, 5- or 6-membered heteroaryl groups, 5- or 6-membered non-aromatic heterocyclic groups, -O-(C 6 -C 10 aryl), -O-(5- or 6-membered heteroaryl), C 1 -C 12Alkylaminocarbonyl group, unsubstituted or halogenated C 2 -C 10 Acyl groups, sulfonyl (-SO 2 -OH), phosphoryl (-PO 3 -OH), unsubstituted or halogenated C 1 -C 4 Alkyl-S(O) 2 -, unsubstituted or halogenated C 1 -C 4 alkyl-SO-.
[0007] In another preferred embodiment, the compound of formula I has the structure as shown in formula II: [ka] wherein X, Y and Z are each independently selected from the group consisting of N or CR. In another preferred embodiment, the compound of formula I has the structure as shown in formula IIa: [ka] wherein the W ring is a substituted or unsubstituted C 6 -C 10 aryl groups, substituted or unsubstituted 4-12 membered heterocyclic rings containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted 5-12 membered heteroaromatic rings containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, substituted or unsubstituted -C 1 -C 6 Alkyl-phenyl groups, substituted or unsubstituted C 3 -C 12 cycloalkyl groups, wherein in the W group, the substitution refers to substitution with one or more groups selected from group A.
[0008] In another preferred embodiment, the W ring is a substituted or unsubstituted 4-7 membered heterocyclic ring, a substituted or unsubstituted 5-6 membered heteroaromatic ring, a substituted or unsubstituted 9-10 membered fused bicyclic heteroaromatic ring, a substituted or unsubstituted phenyl group, a substituted or unsubstituted C 3 -C 6 A group selected from the group consisting of cycloalkyl groups.
[0009] In another preferred embodiment, the W ring is a phenyl group, a cyclopentyl group, a cyclohexyl group, [ka] is a substituted or unsubstituted cyclic structure selected from the group consisting of:
[0010] In another preferred embodiment, the compound of formula I has the structure as shown in formula III: [ka] wherein the ring A is a substituted or unsubstituted 4-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C 6 -C 10 Aryl groups, substituted or unsubstituted -C 1 -C 6 Alkyl-phenyl groups, substituted or unsubstituted C 3 -C 12 cycloalkyl groups, and M is a chemical bond, or -O-, -CHR-, a carbonyl group, S, -NH-, -NHC(O)-, -NHS(O) 2 -, -NHC(O)NH-, -NHC(S)NH-, -COO-, -OS(O) 2 - is selected from the group consisting of In another preferred embodiment, the compound of formula I has the structure as shown in the following formula: [ka] Where: Rf is H, halogen, cyano group, amino group, nitro group, hydroxyl group, mercapto group, aldehyde group, carboxyl group, sulfonyl group, C 1 -C 4 Alkyl-S(O) 2 -, substituted or unsubstituted C 1 -C 6 Alkyl groups, substituted or unsubstituted C 1 -C 6 alkoxy groups; t is 0, 1, 2, 3 or 4; The A ring is a substituted or unsubstituted 5-12 membered saturated ring (including spiro rings and bridged rings), a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C 6 -C 10 aryl groups, said ring having at least one heteroatom selected from N or O. In another preferred embodiment, at least one of the Rf's is located at the meta position of the connection site between the benzene ring and the mother core.
[0011] In another preferred embodiment, the compound of formula I has the structure as shown in the following formula: [ka] Where: Rf is H, halogen, cyano group, amino group, nitro group, hydroxyl group, mercapto group, aldehyde group, carboxyl group, sulfonyl group, C 1 -C 4 Alkyl-S(O) 2 -, substituted or unsubstituted C 1 -C 6 Alkyl groups, substituted or unsubstituted C 1 -C 6 alkoxy groups; t is 0, 1, 2, 3 or 4; L is N or CH; The A ring is a substituted or unsubstituted 4-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen; 3 -C 12 a cycloalkyl group, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C 6 -C 10 aryl groups.
[0012] Where: [ka] When the nitrogen atom above is the attachment site, the NH is N (ie, the hydrogen atom on the NH is lost to form the attachment site). In another preferred embodiment, the compound of formula I has the structure as shown in formula IV: [ka] wherein the A ring is a substituted or unsubstituted 4-7 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C 6 -C 10 Aryl groups, substituted or unsubstituted -C 1 -C 6 Alkyl-phenyl groups, substituted or unsubstituted C 3 -C 12 cycloalkyl groups, M is a chemical bond, -O-, -CHR-, a carbonyl group, S, -NH-, -NHC(O)-, -NHS(O) 2 -, -NHC(O)NH-, -NHC(S)NH-, -COO-, -OS(O) 2 - selected from the group consisting of Ring B is a substituted or unsubstituted 4-12 membered heterocycle (including monocyclic, fused polycyclic, bridged or spirocyclic rings) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen; a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen; a substituted or unsubstituted C 6 -C 10 Aryl groups, substituted or unsubstituted C 3 -C 12 is selected from the group consisting of carbocycles; V is a chemical bond, or -O-, -CHR-, a carbonyl group, S, -NH-, -NHC(O)-, -NHS(O) 2 -, -NHC(O)NH-, -NHC(S)NH-, -COO-, -OS(O) 2 - is selected from the group consisting of
[0013] In another preferred embodiment, the compound of formula I has the structure as shown in the following formula: [ka] Here, Rg is a halogen, a cyano group, an amino group, a nitro group, a hydroxyl group, a mercapto group, an aldehyde group, a carboxyl group, a sulfonyl group, a substituted or unsubstituted C 1 -C 6 Alkyl groups, substituted or unsubstituted C 1 -C 6 alkoxy groups; The B ring is a substituted or unsubstituted 4-12 membered heterocycle (including monocyclic, fused polycyclic, bridged or spiro ring) containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C 6 -C 10 Aryl groups, substituted or unsubstituted C 3 -C 12 is selected from the group consisting of carbocycles; u is 0, 1, 2, 3 or 4.
[0014] In another preferred embodiment, the compound of formula I has the structure as shown in the following formula: [ka] Here, Rg is a halogen, a cyano group, an amino group, a nitro group, a hydroxyl group, a mercapto group, an aldehyde group, a carboxyl group, a sulfonyl group, a substituted or unsubstituted C 1 -C 6 Alkyl groups, substituted or unsubstituted C 1 -C 6 alkoxy groups; u is 0, 1, 2, 3 or 4.
[0015] In another preferred embodiment, the A ring has at least one substituent G, and the G group is an amino group, a substituted or unsubstituted 4-7 membered heterocycle containing 1-3 heteroatoms selected from =O, oxygen and nitrogen, a substituted or unsubstituted C 2 -C 10 Acyl groups, substituted or unsubstituted C 2 -C 10 Ester group, substituted or unsubstituted C 1 -C 6 amide groups.
[0016] Where: [ka] When the nitrogen atom above is the attachment site, the NH is N (ie, the hydrogen atom on the NH is lost to form the attachment site).
[0017] In another preferred embodiment, the compound of formula I has a structure selected from the group consisting of: [ka]
[0018] In another preferred embodiment, W is [ka] is selected from the group consisting of:
[0019] In another preferred embodiment, W is [ka] is selected from the group consisting of:
[0020] In another preferred embodiment, Rc is [ka] is selected from the group consisting of:
[0021] In another preferred embodiment, the URc is [ka] is selected from the group consisting of:
[0022] In another preferred embodiment, Re is an amine group, a substituted or unsubstituted C 1 -C 6 alkyl-NH-.
[0023] A second aspect of the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of one or more of the compounds of formula I according to the first aspect of the invention, their pharma- ceutically acceptable salts, racemates, R-isomers and S-isomers, stereoisomers or tautomers, and one or more pharma- ceutically acceptable carriers, excipients, adjuvants, auxiliary agents and / or diluents.
[0024] A third aspect of the present invention provides the use of a compound of formula I, its racemate, R-isomer, S-isomer or a pharma- ceutically acceptable salt thereof, as described in the first aspect of the present invention, in the preparation of a medicament for treating or preventing a disease associated with a gene level or expression abnormality of a kinase selected from the group consisting of FLT3, ALK, RET, ROS, AXL, EGFR (e.g., a corresponding nucleic acid mutation, deletion, or ectopic or fusion or overexpression by said kinase). In another preferred embodiment, the disease is acute myeloid leukemia, type I neurofibroma, multiple myeloma, malignant glioma, non-small cell lung cancer, liver cancer, hepatocellular carcinoma, cervical cancer, lymphoma, bone metastasis cancer, hormone refractory prostate cancer, hormone dependent prostate cancer, thyroid tumor, medullary thyroid cancer, mesothelioma, glioblastoma, bone metastasis cancer, Merkel cell carcinoma, urogenital tumor, Merkel cell carcinoma, bladder cancer, papillary thyroid cancer, breast cancer, soft tissue sarcoma, glioma, neuroendocrine tumor, renal cell carcinoma, The cancer is selected from the group consisting of advanced solid tumors, anaplastic astrocytic carcinoma, gastrointestinal stromal tumors, Hippel-Lindau syndrome, small cell lung cancer, pancreatic cancer, pancreatic endocrine carcinoma, central nervous system tumors, metastatic renal cancer, endometrial cancer, endometrioid endothelial carcinoma, lung cancer, colorectal cancer, ovarian cancer, rhabdomyosarcoma, melanoma, retinoblastoma, central and peripheral nervous system tumors, acute leukemia, chronic leukemia, bile duct cancer, bronchial cancer, esophageal cancer, testicular cancer, skin cancer, oral cancer, neuroblastoma, and anaplastic large cell lymphoma.
[0025] In another aspect, the present invention provides a conjugate, said conjugate being obtained by linking a compound according to the present invention with a small biological molecule or a monoclonal antibody via chemical bonds. Effect of the Invention
[0026] It should be understood that within the scope of the present invention, the above technical features of the present invention and the technical features specifically described below (e.g., in the Examples) can be combined with each other to form new or preferred technical solutions, which will not be repeated here due to space limitations. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0027] As a result of extensive and thorough research, the present inventors unexpectedly discovered a compound having kinase inhibitory activity (e.g., FLT3, ALK, AXL, EGFR, etc.) for the first time. Based on this discovery, the present invention has been completed.
[0028] term In the present invention, the halogen is F, Cl, Br or I. In the present invention, unless otherwise specified, the terms used have the general meanings known to those skilled in the art.In the present invention, unless otherwise specified, all chemical formulas are intended to represent possible optical isomers or geometric isomers (such as R-form, S-form or racemic compound, or cis-trans isomers of alkenes, etc.).
[0029] In the present invention, "C 1 -C 6 The term "alkyl group" refers to a straight or branched chain alkyl group having 1 to 6 carbon atoms, including, but not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl and hexyl groups, preferably ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl and t-butyl.
[0030] In the present invention, "C 1 -C 6The term "alkoxy group" refers to a straight or branched chain alkoxy group having from 1 to 6 carbon atoms, including, but not limited to, a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, or a butoxy group.
[0031] In the present invention, "C 2 -C 6 The term "alkenyl group" refers to a straight or branched chain alkenyl group having 2 to 6 carbon atoms containing a double bond, including, but not limited to, vinyl group, propenyl group, butenyl group, isobutenyl group, pentenyl group, hexenyl group, and the like.
[0032] In the present invention, "C 2 -C 6 The term "alkynyl group" refers to straight or branched chain alkynyl groups having 2 to 6 carbon atoms containing a triple bond, including, but not limited to, ethynyl group, propynyl group, butynyl group, isobutynyl group, pentynyl group, and hexynyl group.
[0033] In the present invention, "C 3 -C 10The term "cycloalkyl group" refers to a cyclic alkyl group having 3 to 10 carbon atoms in the ring, including, but not limited to, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclooctyl group, and cyclodecyl group. 3 -C 8 Cycloalkyl group, C 3 -C 7 Cycloalkyl groups," and "C 3 -C 6 The term "cycloalkyl group" has an analogous meaning.
[0034] In the present invention, "C 3 -C 10 The term "cycloalkenyl group" refers to a cyclic alkenyl group having 3 to 10 carbon atoms in the ring, including, but not limited to, cyclopropenyl group, cyclobutenyl group, cyclopentenyl group, cyclohexenyl group, cycloheptenyl group, cyclooctenyl group, and cyclodecylene. 3 -C 7 The term "cycloalkenyl group" has an analogous meaning.
[0035] In the present invention, "C 1 -C 12The term "alkoxycarbonyl group" refers to an alkoxycarbonyl group having 1 to 12 carbon atoms in the alkyl chain, including, but not limited to, a methoxycarbonyl group, an ethoxycarbonyl group, a propoxycarbonyl group, an isopropoxycarbonyl group, a t-butoxycarbonyl group, a benzyloxycarbonyl group, and the like.
[0036] In the present invention, "C 1 -C 12 The term "alkylaminocarbonyl group" refers to an alkylaminocarbonyl group having 1 to 12 carbon atoms in the alkyl chain, and includes, but is not limited to, a methylaminocarbonyl group, an ethylaminocarbonyl group, a propylaminocarbonyl group, an isopropylaminocarbonyl group, a t-butylaminocarbonyl group, a benzylaminocarbonyl group, a dimethylaminocarbonyl group, and the like.
[0037] In the present invention, "C 5 -C 9The term "furanosyl group" refers to a furanosyl group having 5 to 9 carbon atoms, where the 1-position of the glycosyl group is linked to the backbone, and includes, but is not limited to, a ribofuranosyl group, a deoxyribofuranosyl group, a galactofuranosyl group, and the like.
[0038] In the present invention, "C 5 -C 9 The term "pyranosyl" refers to a pyranosyl having 5 to 9 carbon atoms where the 1-position of the sugar group is linked to the backbone, including, but not limited to, a glucopyranosyl group, a glucopyranuronosyl group, a rhamnopyranosy group, a galactopyranosyl group, a mannopyranosyl group, a xylopyranosyl group, and the like.
[0039] In the present invention, the terms "aromatic ring" and "aryl group" have the same meaning, and preferably, the "aryl group" is "C 6 -C 12 Aryl group" or "C 6 -C 10 "Aryl group". 6 -C 12 The term "aryl group" refers to an aromatic ring group having 6 to 12 carbon atoms without heteroatoms in the ring, such as a phenyl group, a naphthyl group, and the like. 6 -C 10 The term "aryl group" has an analogous meaning.
[0040] In the present invention, the terms "heteroaromatic ring" or "heteroaryl group" have the same meaning and refer to a heteroaromatic group containing one or more heteroatoms. Heteroatoms referred to herein include oxygen, sulfur and nitrogen. For example, furyl group, thienyl group, pyridyl group, pyrazolyl group, pyrrolyl group, N-alkylpyrrolyl group, pyrimidinyl group, pyrazinyl group, imidazolyl group, tetrazolyl group, etc. The heteroaryl ring can be fused to an aryl group, a heterocyclic group or a cycloalkyl ring, where the ring attached to the parent structure is a heteroaryl ring. The heteroaryl group can be optionally substituted or unsubstituted.
[0041] In the present invention, the term "3- to 12-membered heterocyclic group" refers to a saturated or unsaturated 3- to 12-membered ring group containing 1 to 3 heteroatoms selected from oxygen, sulfur and nitrogen in the ring, such as a dioxolyl group. The term "3- to 7-membered heterocyclic group" has an analogous meaning.
[0042] In the present invention, the term "substituted" refers to the replacement of one or more hydrogen atoms on a particular group by a specified substituent. The specific substituents are the corresponding substituents described above or those shown in each example. Unless otherwise specified, a substituent may have one substituent selected from a specified group at any substitutable position of the group, and the substituents may be the same or different at each position. A cyclic substituent, such as a heterocycloalkyl group, may be bonded to another ring, such as a cycloalkyl group, to form a spiro bicyclic system, e.g., two rings with a common carbon atom. Those skilled in the art will understand that the combination of substituents contemplated by the present invention is stable or chemically feasible. The substituents may be, for example, C 1 -8 alkyl group, C 2-8 Alkenyl group, C 2-8 Alkynyl group, C 3-8 Cycloalkyl groups, 3-12 membered heterocyclic groups, aryl groups, heteroaryl groups, halogens, hydroxyl groups, carboxyl groups (-COOH), C 1-8 Aldehyde group, C 2-10 Acyl group, C 2-10 Ester group, C 1 -C 12 Alkoxycarbonyl group, amino group, alkoxy group, C 1-10 and the like, but not limited to, a sulfonyl group.
[0043] FLT3 inhibitor compounds The present invention provides a compound having FLT3 inhibitory activity, [ka] wherein each group has the above definition.
[0044] In the present application, preferred compounds are those selected from Table 1 below. [Table 1-1] [Table 1-2]
Table 1-3
Table 1-4
Table 1-5
Table 1-6
Table 1-7
Table 1-8
Table 1-9
Table 1-10
Table 1-11
Table 1-12
Table 1-13
Table 1-14
Table 1-15
Table 1-16
Table 1-17
Table 1-18
Table 1-19
[0045] where 162 and 163 are [ka] and [ka] However, the absolute configuration is unknown. 164 and 165 are [ka] and [ka] However, the overall arrangement is unknown. 284 and 285 are [ka] and [ka] However, the absolute configuration is unknown.
[0046] Pharmaceutical Compositions and Methods of Administration Since the compound of the present invention has excellent kinase inhibitory activity, the compound of the present invention and various crystal forms thereof, pharma- ceutically acceptable inorganic or organic salts, hydrates or solvates, as well as pharmaceutical compositions containing the compound of the present invention as a main active ingredient, can be used to treat, prevent and alleviate associated diseases caused by abnormalities in the activity or expression level of kinases (e.g., FLT3).
[0047] The pharmaceutical composition of the present invention contains a safe and effective amount of the compound of the present invention or a pharmacologically acceptable salt thereof and a pharmacologically acceptable excipient or carrier. Here, "safe and effective amount" refers to an amount of the compound sufficient to significantly improve the condition without causing serious side effects. Usually, the pharmaceutical composition contains 1-2000 mg of the compound / agent of the present invention, more preferably 5-200 mg of the compound / agent of the present invention. Preferably, the "one agent" is one capsule or tablet.
[0048] "Pharmaceutically acceptable carrier" refers to one or more compatible solid or liquid fillers or gel substances that must be of sufficient purity and sufficiently low toxicity to be suitable for human use. "Compatibility" refers to the ability of the components of the composition to be blended with each other without significantly decreasing the efficacy of the compounds of the present invention and among themselves. Some examples of pharma- ceutically acceptable carriers include cellulose and its derivatives (e.g., sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (e.g., stearic acid, magnesium stearate), calcium sulfate, vegetable oils (e.g., soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (e.g., propylene glycol, glycerin, mannitol, sorbitol, etc.), emulsifiers (e.g., Tween R), wetting agents (e.g., sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, pyrogen-free water, and the like.
[0049] The mode of administration of the compounds or pharmaceutical compositions of the present invention is not particularly limited, and representative modes of administration include, but are not limited to, oral, intratumoral, rectal, parenteral (intravenous, intramuscular, or subcutaneous), and topical administration.
[0050] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as, for example, sodium citrate or dicalcium phosphate, or with other suitable carriers, such as (a) fillers or compatibilizers, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, such as hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; (c) humectants, such as glycerin; (d) glycerin, or other suitable carriers, such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate. The pharmaceutical composition is mixed with ingredients such as disintegrants such as (a) carbonate, (b) retarders such as paraffin, (c) absorption promoters such as quaternary amine compounds, (d) wetting agents such as cetyl alcohol and glyceryl monostearate, (e) adsorbents such as kaolin, and (f) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets, and pills, the dosage form may also include buffering agents.
[0051] Solid dosage forms such as tablets, sugar pills, capsules, pills and granules can be prepared with coating and shell materials, such as enteric coatings and other materials known in the art. They can contain opacifying agents, and the release of the active compound or compounds of such compositions can be delayed in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. If necessary, the active compound can be formed into microcapsules with one or more of the above-mentioned excipients.
[0052] Liquid dosage forms for oral administration include pharma- ceutically acceptable emulsions, solutions, suspensions, syrups, or tinctures. In addition to the active compound, liquid dosage forms can contain inert diluents conventionally used in the art, such as water or other solvents, and solubilizers and emulsifiers, such as, for example, ethyl carbonate, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butyleneglycol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, or mixtures of these substances.
[0053] Besides these inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring and perfuming agents.
[0054] In addition to the active compound, suspensions may contain suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and dehydrated sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar-agar, or mixtures of these substances.
[0055] Compositions for parenteral injection can include physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols, and suitable mixtures thereof.
[0056] Dosage forms of the compounds of the present invention used for topical administration include ointments, powders, patches, sprays and inhalants. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants which may be required.
[0057] The compounds of the present invention can be administered alone or in combination with other pharma- ceutically acceptable compounds. In some preferred embodiments, the compounds of the present invention can be administered together with other small molecule compounds to form PROTACs or together with other macromolecular compounds, such as other monoclonal antibodies, to form ADCs.
[0058] When a pharmaceutical composition is used, a safe and popular amount of the compound of the present invention is applied to a mammal (e.g., a human) in need of treatment, where the dosage at the time of administration is the effective dosage considered, and for a person weighing 60 kg, the daily dosage is usually 1-2000 mg, preferably 5-500 mg. Of course, the specific dosage must also take into account factors such as the route of administration and the health status of the patient, all of which are within the skill of a skilled physician.
[0059] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and do not limit the scope of the present invention. In the following examples, the experimental methods without specific conditions are usually in accordance with conventional conditions or conditions suggested by manufacturers. Unless otherwise specified, percentages and parts are calculated by weight.
[0060] The definitions of each abbreviation are as follows: [Table 2]
[0061] The raw materials can be obtained from commercial sources or prepared by methods already known or published in the art.
[0062] The purification of intermediates and compounds is carried out by conventional chemical experimental operations such as normal or reversed phase chromatography or recrystallization. Normal phase chromatography is a prepacked silica gel chromatography column or preparative thin layer chromatography. Silica gel chromatography columns are mainly glass columns or high-speed preparative chromatography. The mobile phase of normal phase chromatography is selected from petroleum ether / ethyl acetate, dichloromethane / methanol or other suitable solvents and eluted in a blend ratio. Reverse phase preparative liquid chromatography employs a C18 column, detects using preparative liquid chromatography or high-speed preparative chromatography, 214nM and 254nM or preparative liquid chromatography-mass spectrometry, and uses a gradient elution using water / acetonitrile with 0.1% hydrochloric acid, water / acetonitrile, water / acetonitrile with 0.1% ammonium bicarbonate, water / acetonitrile with 0.1% formic acid, 0.1% ammonia water / acetonitrile, water / acetonitrile with 0.1% trifluoroacetic acid or other suitable solvent system as the mobile phase.
[0063] Characterization of the structures of intermediates and compounds uses the methods of nuclear magnetic resonance (NMR) and mass spectrometry (LCMS). The NMR spectrometers used for nuclear magnetic resonance are Bruker Ascend 400 or Varian 400 or ZKNJ BIXI-1 300MHz or Bruker Avance III 400MHz or Bruker AVANCE Neo 400MHz. The solvents used are deuterated dimethyl sulfoxide, deuterated chloroform, deuterated methanol or other marked deuterated solvents. Spectral data are reported in modes such as chemical shift δ (peak split number, coupling constant J (Hz), number of hydrogens). Tetramethylsilane is used as an internal standard for chemical shifts, and its chemical shift is set to zero (δ, 0 ppm). The meanings of some abbreviations are s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad peak).
[0064] Representative methods for liquid chromatography-mass spectrometry (LCMS) in the structural characterization of intermediates and compounds are as follows. Method 1: Agilent LC coupled to a 6120 single quadrupole mass spectrometer 12 This will be implemented in 60 systems.
[0065] Column: Waters CORTECS C-18, 2.7 μm, 4.6 × 30 mm. Solvent A: 0.05% formic acid in water, Solvent B: 0.05% formic acid in acetonitrile, 5% acetonitrile in 1 min to 95% acetonitrile, hold for 1 min, total 2.5 min, flow rate: 1.8 mL / min, column temperature 40 °C.
[0066] Column: XSelect CSH C 1 8, 3.5 μm, 4.6 × 50 mm. Solvent A: 0.05% aqueous ammonia, Solvent B: 0.05% ammonia in acetonitrile, 5% acetonitrile to 95% acetonitrile in 1 min, hold for 1 min, total 2.5 min, flow rate: 1.8 mL / min, column temperature 40 °C.
[0067] Method 2: performed on an Agilent LC / MSD 1200 system coupled to a quadrupole mass spectrometer. Column: ODS 2000 (50×4.6 mm, 5 μm) (ES (+) or (−) ionization mode), temperature 30° C., flow rate 1.5 mL / min.
[0068] General Method: Synthesis of Compound 8 Example 1: 3-Ethyl-8-(3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-N2-(tetrahydropyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine trihydrochloride (compound 8) [ka]
[0069] Step 1: 1-benzyl-4-piperidone (5.00 g, 26.5 mmol) and 1-t-butoxycarbonylpiperazine (5.41 g, 29.1 mmol) are dissolved in dichloromethane (100 mL), acetic acid (2.38 g, 39.7 mmol) is added, and the mixture is stirred at room temperature for 5 hours. Then sodium triacetoxyborohydride (22.4 g, 106 mmol) is added in batches to the solution, and the mixture is stirred at room temperature overnight. The reaction mixture is concentrated, and the resulting residue is added with water (100 mL), and the pH value is adjusted to 10 with 5% sodium hydroxide. Extract three times with ethyl acetate (50 mL x 3), combine the organic phases, wash the organic phase with saturated brine (50 mL), dry over anhydrous sodium sulfate, filter, concentrate the filtrate under reduced pressure, and purify the resulting residue by C18 reverse phase chromatography column (50% acetonitrile in water to 90% acetonitrile in water) to obtain t-butyl 4-(1-benzylpiperidin-4-yl)piperazine-1-carboxylate as a yellow solid (5.80 g, 61% yield). MS: 360.4 [M+H] + .
[0070] Step 2: t-Butyl 4-(1-benzylpiperidin-4-yl)piperazine-1-carboxylate (5.80 g, 16.1 mmol) is dissolved in methanol (100 mL) and 10% palladium on carbon (1.5 g) is added. The mixture is stirred overnight under hydrogen gas (50 psi) at 50° C. After completion of the reaction, it is cooled to room temperature, filtered, and the filtrate is concentrated under reduced pressure to obtain t-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate as a white solid (4.15 g, 96% yield). 1 H NMR (300 MHz, CDCl 3 ):δ 3.44-3.41(m,4H),3.17-3.13(m,2H),2.63-2.58(m,2H),2.55-2.49(m,4 H),2.41-2.31(m,1H),1.82-1.78(m,2H),1.46(s,9H),1.43-4.33(m,2H).
[0071] Step 3: 1-Fluoro-2-methoxy-4-nitrobenzene (2.00 g, 11.7 mmol) and t-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate (3.46 g, 12.9 mmol) are dissolved in N,N-dimethylformamide (30 mL), and potassium carbonate (3.23 g, 23.4 mmol) is added. The mixture is reacted for 2 hours under stirring at 100°C. After the reaction is complete, it is cooled to room temperature, water (100 mL) is added, and the mixture is extracted twice with ethyl acetate (30 mL x 2), and the organic phases are combined. The organic phase is washed twice with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to give a yellow solid, t-butyl 4-(1-(2-(2-methoxy-4-nitrophenyl)piperidin-4-yl)piperazine-1-carboxylate (4.90 g, 99% yield). 421.0 [M+1] + .
[0072] Step 4: t-Butyl 4-(1-(2-(2-methoxy-4-nitrophenyl)piperidin-4-yl)piperazine-1-carboxylate (4.90 g, 11.7 mmol) is dissolved in methanol (50 mL) and 10% palladium on carbon (0.5 g) is added. The mixture is stirred overnight under hydrogen gas (hydrogen balloon) at 50° C. After completion of the reaction, it is cooled to room temperature, filtered, and the filtrate is concentrated under reduced pressure to give t-butyl 4-(1-(4-amino-2-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylate as a purple solid (4.50 g, 99% yield). 1H NMR (400 MHz, CDCl 3 ):δ 6.77(d,J=8.4Hz,1H),6.26-6.23(m,2H),3.81(s,3H),3.50-3.38(m,8H),2.55-2 .54(m,2H),2.50-2.47(m,2H),2.45-2.37(m,1H),1.83-1.78(m,4H),1.46(s,9H).
[0073] Step 5: t-Butyl 4-(1-(4-amino-2-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylate (3.40 g, 8.72 mmol) and diiodomethane (7.00 g, 26.1 mmol) are dissolved in acetonitrile (100 mL) and isoamyl nitrite (1.53 g, 13.1 mmol) is added. The mixture is reacted under nitrogen gas protection at 80° C. with stirring for 4 hours. After completion of the reaction, it is cooled to room temperature and concentrated under reduced pressure, and dichloromethane (30 mL), water (20 mL), and saturated sodium carbonate solution (10 mL) are added to the obtained residue. The mixture is extracted three times with dichloromethane (20 mL×3). The organic phases are combined, the organic phase is washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by silica gel chromatography column (petroleum ether / ethyl acetate=2:1 to ethyl acetate) to give t-butyl 4-(4-(4-iodo-2-methoxyphenyl)cyclohexyl)piperazine-1-carboxylate as a brown solid (1.85 g, 42% yield). 1 H NMR (300 MHz, CDCl 3)δ 7.21(dd,J=8.1,1.8Hz,1H),7.09(d,J=1.5Hz,1H),6.65(d,J=8.4Hz,1H),3.84(s,3H),3.52-3.48 (m,2H),3.46-3.42(m,4H),2.56-2.47(m,6H),2.42-2.38(m,1H),1.87-1.74(m,4H),1.46(s,9H). MS:502.5[M+H] + .
[0074] Step 6: t-Butyl 4-(4-(4-iodo-2-methoxyphenyl)cyclohexyl)piperazine-1-carboxylate (1.85 g, 3.69 mmol) is dissolved in N,N-dimethylformamide (100 mL), and pinacol diboronic acid (1.13 g, 4.43 mmol), potassium acetate (1.09 g, 11.1 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (135 mg, 0.17 mmol) are added. The mixture is reacted under nitrogen gas protection at 100 °C with stirring for 5 hours. After completion of the reaction, it is cooled to room temperature, poured into water (100 mL), and saturated sodium carbonate solution (10 mL) is added. The mixture is extracted three times with ethyl acetate (30 mL x 3). Combine the organic phases, wash the organic phase with saturated brine (10 mL), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. Purify the resulting residue by silica gel chromatography column (petroleum ether / ethyl acetate=1:1 to ethyl acetate) to obtain 4-(1-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yl)-1-t-butoxycarbonylpiperazine as a yellow solid (intermediate A, 1.30 g, 70% yield). 1 H NMR (300 MHz, CDCl 3)δ 7.39(d,J=7.8Hz,1H),7.25(s,1H),6.93(d,J=7.8Hz,1H),3.91(s,3H),3.64-3.60(m,2H),3.46- 3.43(m,4H),2.62-2.55(m,6H),2.50-2.41(m,1H),1.89-1.76(m,4H),1.47(s,9H),1.33(s,12H). MS:502.6[M+H] + .
[0075] Step 7: 5-Bromo-2-chloropyridine-3,4-diamine (5.00 g, 22.5 mmol) and 2-oxobutanoic acid ethyl ester (3.51 g, 27.0 mmol) are dissolved in ethanol (100 mL), and acetic acid (0.2 mL) is added. The mixture is reacted under nitrogen gas protection at 90 °C with stirring for 36 hours. After the reaction is completed, it is cooled to 50 °C, filtered, and the filter cake is washed with ethanol (10 mL × 3). The filtrate is concentrated under reduced pressure, and the resulting residue is dissolved in ethanol (20 mL), heated to reflux for 10 minutes, then cooled to 50 °C, filtered, and the filter cake is washed with ethanol (10 mL × 2), and dried to obtain 8-bromo-5-chloro-3-ethylpyrido[3,4-b]pyrazin-2(1H)-one as a yellow solid (4.1 g, 63% yield). 1 H NMR (400MHz, DMSO-d 6 )δ 12.32(br s,1H),8.50(s,1H),2.86(q,J=7.6Hz,2H),1.25(t,J=7.6Hz,3H).
[0076] Step 8: 8-Bromo-5-chloro-3-ethylpyrido[3,4-b]pyrazin-2(1H)-one (3.10 g, 10.7 mmol) is suspended in dichloromethane (50 mL) and 5 drops of N,N-dimethylformamide and oxalyl chloride (5.46 g, 43.0 mmol) are added. The mixture is reacted overnight under nitrogen gas protection at 40 °C with stirring. After completion of the reaction, it is cooled to room temperature and concentrated under reduced pressure, and the obtained residue is added with dichloromethane (50 mL), water (30 mL), and saturated sodium carbonate solution (10 mL). The mixture is extracted five times with dichloromethane (30 mL x 5). Combine the organic phases, wash the organic phase with saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to give 8-bromo-2,5-dichloro-3-ethylpyrido[3,4-b]pyrazine as a yellow solid (2.0 g, 61% yield). 1 H NMR (300MHz, DMSO-d 6 )δ 8.91(s,1H),3.20(q,J=7.2Hz,2H),1.39(t,J=7.2Hz,3H).
[0077] Step 9: Tetrahydropyran-4-amine (1.35 g, 9.77 mmol) is suspended in ethanol (20 mL), N,N-diisopropylethylamine (2.52 g, 19.5 mmol) is added, and the mixture is stirred at room temperature for 30 minutes. 8-Bromo-2,5-dichloro-3-ethylpyrido[3,4-b]pyrazine (2.00 g, 6.51 mmol) is suspended in ethanol (30 mL), N,N-diisopropylethylamine (1.68 g, 13.0 mmol) is added, and the mixture is stirred at room temperature for 30 minutes. The above two solutions are combined and reacted overnight under stirring at 70°C. After the reaction is completed, the mixture is cooled to room temperature and concentrated under reduced pressure. The resulting residue is added with water (30 mL) and filtered. Wash the filter cake with dichloromethane / methanol = 10 / 1 (5 mL × 3) and dry to obtain a yellow solid of 8-bromo-5-chloro-3-ethyl-N-(tetrahydropyran-4-yl)pyrido[3,4-b]pyrazin-2-amine (1.2 g, 50% yield). 1 H NMR (300MHz, DMSO-d 6)δ 8.50(s,1H),7.81(d,J=7.2Hz,1H),4.42-4.31(m,1H),3.98-3.94(m,2H),3.43(t,J=7.5H z,2H),2.92(q,J=7.2Hz,2H),1.98-1.93(m,2H),1.80-1.66(m,2H),1.31(t,J=7.2Hz,3H).
[0078] Step 10: To a mixture of 8-bromo-5-chloro-3-ethyl-N-(tetrahydropyran-4-yl)pyrido[3,4-b]pyrazine-2-amine (0.960 g, 2.59 mmol) and 4-(1-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yl)-1-t-butoxycarbonylpiperazine (Intermediate A, 1.30 g, 2.59 mmol) in N,N-dimethylacetamide (50 mL), add aqueous sodium carbonate (824 mg, 7.78 mmol) (5 mL) and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (190 mg, 0.26 mmol). The mixture is reacted under nitrogen gas protection at 100 ° C for 3 hours with stirring. After the reaction is complete, the mixture is cooled to room temperature and poured into water (150 mL). The mixture is extracted three times with ethyl acetate (30 mL x 3). The organic phases are combined, the organic phase is washed with saturated saline (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by a silica gel chromatography column (ethyl acetate to dichloromethane / methanol / 25% aqueous ammonia = 30:1:0.1) to obtain a crude product. The crude product is purified by a C18 reverse phase chromatography column (50% acetonitrile in water to 80% acetonitrile in water) to obtain a yellow solid t-butyl 4-(1-(4-(5-chloro-3-ethyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyridyl[3,4-b]pyrazin-8-yl)-2-methoxyphenyl)piperidin-4-ylpiperazine-1-carboxylate (0.60 g, 35% yield). 1 H NMR (300MHz, DMSO-d 6)δ 8.32(s,1H),7.56(d,J=7.2Hz,1H),7.30-7.28(m,2H),6.97-6.95(m,1H),4.19-4.11(m,1H),3.93-3.89(m,2H),3.83(s,3H),3.52-3.49(m,2H),3.31-3.30(m,4H),3.25-3.22(m,2H),2.90(q,J=7.2Hz,2H),2.61-2.57(m,2H),2.50-2.41(m,4H),2.38-2.32(m,1H),1.88-1.81(m,4H),1.71-1.55(m,4H),1.40(s,9H),1.32(t,J=7.2Hz,3H)。MS Found:666.8[M+H] + 。
[0079] Step 11: t-Butyl 4-(1-(4-(5-chloro-3-ethyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyridyl[3,4-b]pyrazin-8-yl)-2-methoxyphenyl)piperidin-4-ylpiperazine-1-carboxylate (0.30 g, 0.45 mmol), (2,4-dimethoxyphenyl)methylamine (113 mg, 0.680 mmol), 4,5-bis(diphenylphosphine) To a mixture of 1,0-dimethylxanthene (26 mg, 0.045 mmol) and sodium t-butoxide (130 mg, 1.35 mmol) in toluene (10 mL), tris(dibenzylideneacetone)dipalladium (21 mg, 0.024 mmol) was added. The mixture was reacted for 3 hours under nitrogen gas protection at 110°C with stirring. After the reaction was completed, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was diluted with ethyl acetate (2 Add 100 mL) and water (30 mL). Extract the mixture with ethyl acetate (10 mL x 3) three times. Combine the organic phases, wash the organic phase with saturated brine (10 mL), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. Purify the resulting residue by silica gel chromatography column (dichloromethane / methanol = 30:1) to obtain the crude product. Purify the crude product by C18 reverse phase chromatography column (40% acetonitrile in water to 90% acetonitrile in water) to obtain a yellow solid t-butyl 4-(1-(4-(5-((2,4-dimethoxybenzyl)amino)-3-ethyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyridyl[3,4-b]pyrazin-8-yl)-2-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylic acid (0.13 g, 36% yield). 1 H NMR (400 MHz, CDCl 3)δ 8.16(s,1H),7.35-7.33(m,1H),7.30-7.27(m,1H),7.16(s,1H),6.96-6.94(m,2H),6.50-6.49(m,1H),6. 46-6.43(m,1H),4.80-4.78(m,2H),4.76-4.74(m,1H),4.25-4.16(m,1H),4.01-3.98(m,2H),3.89-3.88(m ,6H),3.80(s,3H),3.62-3.59(m,2H),3.50-3.45(m,6H),2.70(q,J=7.2Hz,2H),2.64-2.59(m,6H),2.53- 2.45(m,1H),2.08-2.05(m,2H),1.89-1.82(m,4H),1.56-1.52(m,2H),1.47(s,9H),1.41(t,J=7.2Hz,3H). MS:797.5[M+H] + .
[0080] Step 12: t-Butyl 4-(1-(4-(5-((2,4-dimethoxybenzyl)amino)-3-ethyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyridyl[3,4-b]pyrazin-8-yl)-2-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylic acid (0.13 g, 0.16 mmol) in dichloromethane (2 mL) is added with trifluoroacetic acid (1 mL) and stirred at 30° C. for 1 hour. The reaction mixture is concentrated, and water (2 mL) is added to the resulting residue and the pH value is adjusted to 10 with 5% sodium hydroxide. Extract six times with dichloromethane / methanol = 10 / 1 (10 mL x 6), combine the organic phases, wash the organic phase with saturated brine (5 mL), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain a yellow solid 3-ethyl-8-(3-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyridine[3,4-b]pyrazine-2,5-diamine (90 mg, 100% yield). MS: 547.6 [M+H] + .
[0081] Step 13: 3-Ethyl-8-(3-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyridine[3,4-b]pyrazine-2,5-diamine (90 mg, 0.16 mmol) in dichloromethane (2 mL) and methanol (1 mL) is added with 37% aqueous formaldehyde solution (15 mg, 0.18 mmol) and a drop of acetic acid. After stirring for 20 minutes at room temperature, sodium cyanoborohydride (31 mg, 0.49 mmol) is added. After reacting for 30 minutes under stirring at room temperature, water (2 mL) is added and the pH value is adjusted to 10 with 5% sodium hydroxide. The mixture is extracted six times with dichloromethane / methanol=10 / 1 (10 mL×6), the organic phases are combined and concentrated under reduced pressure to obtain the crude product. The crude product is purified by C18 reverse phase chromatography column (10% acetonitrile in water to 50% acetonitrile in water, 0.1% hydrochloric acid in water phase) to give 3-ethyl-8-(3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyridine[3,4-b]pyrazine-2,5-diamine trihydrochloride as a yellow solid (65 mg, 61% yield). 1 H NMR (400MHz, DMSO-d 6 )δ 13.77(s,1H),12.48-12.17(m,2H),8.54(s,2H),7.96-7.94(m,2H),7.55(br s,1H),7.43-7.32(m,2H),4.14-4.05(m,1H),3.95(s,3H),3.92-3.89(m,2H),3.79-3.60(m,12H),3.35-3.27(m,1H), 3.25-3.22(m,2H),2.92-2.86(m,5H),2.35-2.25(m,4H),1.83-1.78(m,2H),1.74-1.64(m,2H),1.33(t,J=7.2Hz,3H). MS:561.4[M+H] + .
[0082] Using similar methods and substituting other reaction starting materials, the compounds in the table are prepared. With reference to the synthesis method of compound 8, the compounds in the following table are prepared by replacing tetrahydropyran-4-amine in step 9 with the corresponding starting material in the table below. [Table 3]
[0083] With reference to the synthesis method of compound 8, in step 9, tetrahydropyran-4-amine is replaced with the corresponding starting material in the following table, and in the product corresponding to step 11, the acetyl protecting group is hydrolyzed by an alkaline method to prepare the compound in the following table. [Table 4]
[0084] With reference to the synthesis method of compound 8, in step 3, replace 1-fluoro-2-methoxy-4-nitrobenzene with the corresponding starting material in the table below to prepare the compounds in the table below. [Table 5-1] [Table 5-2]
[0085] Referring to the synthesis method of compound 8, intermediate A is replaced with the starting material in the table below, and reacted with 8-bromo-5-chloro-3-ethyl-N-(tetrahydropyran-4-yl)pyrido[3,4-b]pyrazin-2-amine to prepare the corresponding compound in the table below. [Table 6]
[0086] The product of step 10 in the synthesis of compound 8 is compound 12 in the table below. [Table 7]
[0087] Compound 11 in the following table is prepared starting from compound 12 with reference to the deprotection method in step 12 in the synthesis method of compound 8. [Table 8]
[0088] Referring to the method of Example 11, compound 11 is reacted with the starting materials in the table below to give the compounds in the table below. [Table 9]
[0089] With reference to the synthesis of compound 8, by replacing (2,4-dimethoxyphenyl)methylamine with trimethylboroxane in step 11 and using the Suzuki reaction, the compounds in the following table are prepared. [Table 10]
[0090] With reference to the synthesis method of compound 8, in step 7, replace 2-oxobutanoic acid ethyl ester with the starting material in the table below to prepare the compound in the table below. [Table 11]
[0091] With reference to the synthesis method of Compound 8, in Step 3, replace t-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate with the starting materials in the table below to prepare the compounds in the table below. [Table 12]
[0092] Example 2: The intermediate t-butyl 4-(1-(4-(5-((2,4-dimethoxybenzyl)amino)-3-ethyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[3,4-b]pyrazin-8-yl)-2-methoxyphenyl)piperidin-4-yl)piperazine-1-carboxylic acid produced in step 11 of Example 1 can be synthesized by the following method, followed by steps 12 and 13 of Example 1 to give compound 8. [ka] Step 1: A mixture of 8-bromo-5-chloro-3-ethyl-N-(tetrahydropyran-4-yl)pyrido[3,4-b]pyrazine-2-amine (6.00 g, 16.1 mmol) and 2,4-dimethoxybenzylamine (15 g, 90 mmol) is reacted overnight under stirring at 145° C. After completion of the reaction, the mixture is cooled to room temperature and purified by silica gel chromatography column (petroleum ether / ethyl acetate=5:1 to 3:1) to obtain a yellow solid 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (5.5 g, 68% yield). MS Found: 502.5 [M+H] + .
[0093] Step 2: A mixture of 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (4.00 g, 7.97 mmol) and intermediate A (4.0 g, 7.97 mmol) in 1,4-dioxane (100 mL) was added with cesium carbonate (5.20 g, 15.9 mmol) in water (15 mL) and Pd(dppf)Cl 2(583 mg, 0.80 mmol) is added. The mixture is reacted under nitrogen gas protection at 110° C. with stirring for 3 hours. After completion of the reaction, it is cooled to room temperature, concentrated under reduced pressure, and ethyl acetate (50 mL) and water (50 mL) are added. The mixture is extracted three times with ethyl acetate (50 mL×3). The organic phases are combined, the organic phase is washed with saturated saline (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The obtained residue is purified by silica gel chromatography column (petroleum ether / ethyl acetate=1:1 to 0:1, then ethyl acetate / methanol=20:1) to obtain intermediate B (3.1 g, 49% yield) as a yellow solid.
[0094] Refer to the method of Step 9 in Example 1, replace tetrahydropyran-4-amine with the corresponding starting material in the following table, and react with it; refer to the synthesis method of compound 8 proposed in Example 2, and react with intermediate M to prepare the compound in the following table. [Table 13]
[0095] With reference to the synthesis method of compound 8 in Example 1, and replacing tetrahydropyran-4-amine in step 9 with the corresponding starting material in the table below, the compounds in the table below are prepared with reference to the method in Example 2. [Table 14]
[0096] Substituting 2,4-dimethoxybenzylamine with methylamine as the starting material, and following the synthesis method of Example 2, compound 10 is obtained as follows: [Table 15]
[0097] By replacing 1-fluoro-2-methoxy-4-nitrobenzene with the starting materials in the following table and referring to the synthesis method of intermediate A in Example 1 and the synthesis method in Example 2, compound 23 as follows is obtained. [Table 16]
[0098] By replacing 1-fluoro-2-methoxy-4-nitrobenzene and t-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate with 1-fluoro-2-methyl-4-nitrobenzene and t-butyl 3,9-diazaspiro[5.5]undecane-3-carboxylate in the following table, respectively, and referring to the synthesis method of intermediate A in Example 1 and the synthesis method in Example 2, compound 31 as follows is obtained. [Table 17]
[0099] By replacing t-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate with the starting materials in the following table and referring to the synthesis method of intermediate A in Example 1 and the synthesis method in Example 2, the following compounds are obtained. [Table 18]
[0100] By replacing 1-benzyl-4-piperidone with the starting materials in the following table and referring to the synthesis method of intermediate A in Example 1 and the synthesis method in Example 2, the following compounds are obtained. [Table 19]
[0101] Referring to the synthesis method of Example 1, in step 7, replace 2-oxobutanoic acid ethyl ester with the starting materials in the table below, and referring to the synthesis method of Example 2, the compounds in the table below are obtained. [Table 20]
[0102] By replacing t-butyl 4-(4-(4-iodo-2-methoxyphenyl)cyclohexyl)piperazine-1-carboxylate with the starting materials in the following table and referring to the synthesis method of intermediate A in Example 1 and the synthesis method in Example 2, the following compounds are obtained. [Table 21]
[0103] Example 3: 3-Ethyl-8-(6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)pyridin-3-yl)-N2-tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (compound 21) [ka]
[0104] Step 1: 5-Bromo-2-fluoropyridine (500 mg, 2.84 mmol) and 1-methyl-4-(4-piperidinyl)piperazine (520 mg, 2.84 mmol) are dissolved in N,N-dimethylformamide (10 mL), and potassium carbonate (784 mg, 5.68 mmol) is added. The mixture is reacted under stirring at 110 °C for 6 hours. After the reaction is completed, it is cooled to room temperature, water (40 mL) is added, and the organic phase is extracted with ethyl acetate (20 mL x 3), and the organic phase is combined. The organic phase is washed with saturated saline (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure, and the obtained residue is purified by silica gel chromatography column (dichloromethane:methanol = 20:1 to 10:1) to obtain a white solid (800 mg, 83% yield). 1 H NMR (400 MHz, CDCl 3):δ 8.16(d,J=2.0Hz,1H),7.49(dd,J=8.8,2.0Hz,1H),6.56(d,J=8.8Hz,1H),4.29-4.26(m,2H),2.86-2 .79(m,2H),2.71-2.55(m,4H),2.49-2.42(m,5H),2.28(s,3H),1.93-1.85(m,2H),1.57-1.47(m,2H).
[0105] Step 2: A mixture of 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (800 mg, 1.59 mmol) and divaleryldiboron (810 mg, 3.19 mmol) in N,N-dimethylformamide (5 mL) was added with potassium acetate (364 mg, 3.19 mmol) and Pd(dppf)Cl. 2 (117 mg, 0.16 mmol) is added. The mixture is reacted under nitrogen gas protection at 110° C. with stirring for 5 hours. After the reaction is completed, it is cooled to room temperature and water (30 mL) is added. The mixture is extracted three times with ethyl acetate (20 mL×3). The organic phases are combined, washed with saturated saline (5 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The obtained residue is purified by silica gel chromatography column (petroleum ether / ethyl acetate=1:1 to 0:1 to ethyl acetate / methanol=10:1) to obtain intermediate C as a brown solid (230 mg, 31% yield). MS Found: 468.6 [M+H] + .
[0106] Step 3: Refer to the method of Step 2 of Example 2, react 1-(1-(5-bromopyridin-2-yl)piperidin-4-yl)-4-methylpiperazine (87 mg, 0.26 mmol) with intermediate C (100 mg, 0.21 mmol) to obtain yellow solid N5-(2,4-dimethoxybenzyl)-3-ethyl-8-(6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)pyridin-3-yl)-N2-(tetrahydro-2H)pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (70 mg, 49% yield). MS Found: 682.6 [M+H] + .
[0107] Step 4: Refer to the method of step 12 of Example 1, react with N5-(2,4-dimethoxybenzyl)-3-ethyl-8-(6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)pyridin-3-yl)-N2-(tetrahydro-2H)pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (70 mg, 0.1 mmol) to obtain compound 21 (70 mg, 0.1 mmol) as a yellow solid. 1 H NMR (400MHz, DMSO-d 6 ):δ 8.38(d,J=2.0Hz,1H),7.92-7.88(m,2H),7.05(d,J=6.8Hz,1H),6.85(d,J=8 .8Hz,1H),6.45(s,2H),4.35-4.31(m,2H),4.11-4.03(m,1H),3.93-3.91(m,2 H),3.40-3.28(m,4H),2.83-2.78(m,4H),2.42-2.30(m,7H),2.14(s,3H),1. 89-1.80(m,4H),1.66-1.57(m,2H),1.44-1.34(m,2H),1.31(t,J=7.2Hz,3H). MS Found: 532.3 [M+H] + .
[0108] Example 4: 3-Ethyl-8-(4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-3-(methylsulfonyl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (compound 18) [ka]
[0109] Step 1: Commercially available 1-chloro-2-(methylsulfonyl)-4-nitrobenzene (1.20 g, 5.08 mmol) and 1-methyl-4-(4-piperidinyl)piperazine (931 mg, 5.08 mmol) are dissolved in dimethyl sulfoxide (20 mL) and potassium carbonate (1.40 g, 10.2 mmol) is added. The mixture is reacted under stirring at 100 °C for 2 hours. After the reaction is completed, it is cooled to room temperature, poured into water (100 mL), extracted with ethyl acetate (20 mL x 5), and the organic phases are combined. The organic phase is washed with saturated brine (10 mL x 2) and concentrated under reduced pressure. Dichloromethane (20 mL) is added, poured into an aqueous solution (30 mL) of concentrated hydrochloric acid (3 mL), and washed with dichloromethane (20 mL). The pH value of the aqueous phase is made alkaline with 5% sodium hydroxide solution and extracted with dichloromethane (20 mL x 4). Combine the organic phases, wash the organic phase with saturated brine (5 mL), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to give a brown solid (1.70 g, 87% yield). [M+H] + . 1 H NMR (400 MHz, CDCl 3 )δ 8.95(d,J=2.8Hz,1H),8.42(dd,J=8.8,2.8Hz,1H),7.44(d,J=9.2Hz,1H),3.55-3.52(m,2H),3.32(s,3H),2.87-2.81 (m,2H),2.73-2.65(m,4H),2.58-2.50(m,4H),2.43-2.34(m,1H),2.30(s,1H),2.08-2.05(m,2H),1.82-1.72(m,2H). MS Found:383.2.
[0110] Step 2: Refer to the method of Step 4 of Example 1, starting from 1-methyl-4-(1-(2-(methylsulfonyl)-4-nitrophenyl)piperidin-4-yl)piperazine to obtain a white solid 4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-3-(methylsulfonyl)aniline (1.50 g, 96% yield). MS Found: 353.5 [M+H] + .
[0111] Step 3: 4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)-3-(methylsulfonyl)aniline (600 mg, 1.70 mmol) is dissolved in an aqueous solution (5 mL) of concentrated sulfuric acid (834 mg, 8.51 mmol). Cool to 0° C., add an aqueous solution (0.5 mL) of sodium nitrite (117 mg, 8.51 mmol) dropwise, and stir at 0-5° C. for 10 minutes. Then add an aqueous solution (2 mL) of potassium iodide (565 mg, 3.40 mmol) dropwise, and stir at 5° C. for 30 minutes. Pour into water (5 mL), make alkaline with 5% sodium hydroxide solution to pH 10, and extract with dichloromethane (20 mL×3). Combine the organic phases, wash the organic phase with saturated brine (5 mL), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The resulting residue was purified by silica gel chromatography column (dichloromethane / methanol = 10:1) and then C 1 Purify by 8 columns (40-80% acetonitrile in water) to give a yellow solid (250 mg, 32% yield). MS Found: 464.1 [M+H] + .
[0112] Steps 4 and 5: Referring to the method of Steps 3 and 4 of Example 3, 1-(1-(4-iodo-2-(methylsulfonyl)phenyl)piperidin-4-yl)-4-methylpiperazine (87 mg, 0.26 mmol) is reacted with Intermediate C (200 mg, 0.43 mmol) to give compound 18 as a yellow solid (60 mg, two-step yield 46%). 1 H NMR (400MHz, DMSO-d 6)δ 8.46(d,J=1.2Hz,1H),7.98(s,1H),7.91(d,J=8.4Hz,1H),7.55(d,J=8.4Hz,1H),7. 06(d,J=7.6Hz,1H),6.62(s,2H),4.28-4.18(m,1H),3.84-3.82(m,2H),3.40(s,3H), 3.38-3.32(m,4H),3.26-3.23(m,2H),2.84-2.77(m,5H),2.73-2.59(m,6H),2.37(s, 3H), 1.93-1.91 (m, 2H), 1.82-1.79 (m, 2H), 1.64-1.57 (m, 4H), 1.31 (t, J=7.2Hz, 3H). MS Found:609.4[M+H] + .
[0113] Example 5: 2-(5-(5-amino-3-ethyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[3,4-b]pyrazin-8-yl)-2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)propan-2-ol (compound 19) [ka]
[0114] Step 1: Refer to the method of Step 1 of Example 4, react 1-(5-bromo-2-fluorophenyl)ethanone (1.20 g, 5.53 mmol) with 1-methyl-4-(4-piperidinyl)piperazine (1.01 g, 5.53 mmol) to obtain a yellow solid (1.40 g, 67% yield). MS Found: 380.1 [M+H] + .
[0115] Step 2: Under nitrogen gas protection at 0°C, add dropwise 1-(5-bromo-2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-1-one (400mg, 1.05mmol) in tetrahydrofuran (10mL) to a solution of methylmagnesium bromide in tetrahydrofuran (3.0M, 1.05mL, 3.16mmol). Stir for 1 hour at 0-5°C, pour into water (10mL), extract with dichloromethane / methanol (10 / 1, 10mL x 3), combine the organic phases, and concentrate under reduced pressure. The resulting residue is C 1 Purify by 8 columns (10-60% acetonitrile in water) to give a white solid (170 mg, 41% yield).
[0116] Steps 3 and 4: Referring to the method of Steps 3 and 4 of Example 3, react 2-(5-bromo-2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)propan-2-ol (102 mg, 0.26 mmol) with intermediate C (120 mg, 0.26 mmol) to obtain compound 19 as a white solid (60 mg, 30% yield for two steps). 1 H NMR (400MHz, DMSO-d 6 ):δ 7.92(s,1H),7.64-7.61(m,2H),7.54(br,1H),7.39(d,J=8.0Hz,1H),7.01(d,J=7.2 Hz,1H),6.52(s,2H),4.20-4.12(m,1H),3.90-3.88(m,2H),3.30-3.27(m,4H),2.97 -2.88(m,4H),2.81(q,J=7.2Hz,2H),2.74-2.59(m,7H),2.37(s,3H),1.95-1.92(m, 2H),1.84-1.80(m,2H),1.67-1.58(m,2H),1.57-1.48(m,8H),1.31(t,J=7.2Hz,3H). MS Found:589.4[M+H] + .
[0117] Example 6: 3-Ethyl-8-(3-((4-(4-methylpiperazin-1-yl)piperidin-1-yl)methyl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (compound 43) [ka]
[0118] Step 1: Referring to the method of Step 2 of Example 2, react 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (150 mg, 0.3 mmol) with 3-formylphenylboronic acid (54 mg, 0.36 mmol) to obtain intermediate B as a yellow solid (110 mg, 69% yield).
[0119] Step 2: Add one drop of acetic acid to a mixture of 3-(5-((2,4-dimethoxybenzyl)amino)-3-ethyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[3,4-b]pyrazin-8-yl)benzaldehyde (110 mg, 0.21 mmol) and 1-methyl-4-(piperidin-4-yl)piperazine (57 mg, 0.31 mmol) in dichloromethane (5 mL). Stir at room temperature for 5 hours, then add sodium triacetoxyborohydride (133 mg, 0.63 mmol). After stirring overnight at room temperature, add water (5 mL). Extract the mixture with dichloromethane (15 mL x 4), combine the organic phase, wash the organic phase with saturated brine (5 mL), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The resulting residue is purified by silica gel chromatography column (dichloromethane / methanol=30:1 to 15:1) to give a yellow solid (100 mg, 69% yield). MS Found: 695.7 [M+H] + .
[0120] Step 3: Refer to the deprotection method in step 12 of the synthesis method of compound 8, and prepare compound 43 as a white solid (40 mg, 61% yield) using N5-(2,4-dimethoxybenzyl)-3-ethyl-8-(3-((4-(4-methylpiperazin-1-yl)piperidin-1-yl)methyl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (80 mg, 0.12 mmol) as the starting material. 1 H NMR (400MHz, DMSO-d 6 )δ 8.01(s,1H),7.76-7.71(m,2H),7.42-7.38(m,2H),7.16(d,J=7.2Hz,2H),6.75(s,2H),4.13-4.04(m,1H),3.93-3.90(m,3H),3.3 2-3.26(m,5H),3.15-3.06(m,3H),2.93-2.72(m,10H),2.54(s,3H),1.86-1.84(m,4H),1.70-1.61(m,4H),1.31(t,J=7.2Hz,3H). MS Found:545.3[M+H] + .
[0121] Example 7: 3-Ethyl-8-(3-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (compound 45) [ka]
[0122] Step 1: A mixture of 1-methyl-4-(piperidin-4-ylmethyl)piperazine (1.0 g, 5.1 mmol) and 1-bromo-4-chloro-2-methoxybenzene (1.1 g, 5.1 mmol) in 1,4-dioxane (15 mL) was treated with cesium acetate (5.0 g, 15 mmol) and Pd 2 (dba) 3(0.50 g, 0.50 mmol), BINAP (0.60 g, 1.0 mmol) are added. The mixture is reacted under nitrogen gas protection at 110° C. with stirring for 3 hours. After the reaction is completed, it is cooled to room temperature and water (30 mL) is added. The mixture is extracted three times with ethyl acetate (20 mL×3). The organic phases are combined, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The obtained residue is purified by silica gel chromatography column (dichloromethane / methanol=4:1) to give a yellow oil (620 mg, 35% yield). (ESI) m / z 338.1. [M+H] + .
[0123] Step 2: A mixture of 1-((1-(4-chloro-2-methoxyphenyl)piperidin-4-yl)methyl)-4-methylpiperazine (400 mg, 1.2 mmol) and divaleryldiboron (601 mg, 2.4 mmol) in 1,4-dioxane (10 mL) was added with potassium acetate (291 mg, 3.6 mmol), Pd(dba) 2 (14 mg, 0.020 mmol) and X-Phos (11 mg, 0.020 mmol) are added. The mixture is reacted under nitrogen gas protection at 110° C. with stirring for 16 hours. After completion of the reaction, it is cooled to room temperature, filtered and concentrated under reduced pressure. The obtained residue is purified by silica gel chromatography column (dichloromethane / methanol=4:1) to give a yellow oil (400 mg, 75% yield). (ESI) m / z 430.2. [M+H] + .
[0124] Step 3: Referring to the method of Step 2 of Example 2, react 1-((1-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yl)methyl)-4-methylpiperazine (137 mg, 0.31 mmol) with 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (100 mg, 0.21 mmol) to obtain a yellow oil (112 mg, 79% yield). (ESI) m / z 725.3. [M+H]+ .
[0125] Step 4: N5-(2,4-dimethoxybenzyl)-3-ethyl-8-(3-methoxy-4-(4-((4-methylpiperazin-1-yl)methyl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (112 mg, 0.16 mmol) is dissolved in a solution of hydrochloric acid in methanol (4 M, 5 mL) and reacted under stirring at 25° C. for 16 hours. After completion of the reaction, it is cooled to room temperature and quenched with saturated sodium bicarbonate solution (10 mL). The mixture is extracted three times with ethyl acetate (10 mL×3). The organic phases are combined, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by preparative liquid chromatography to give the formate salt of compound 45 as a yellow solid (19 mg, 20% yield). 1 H NMR (400MHz, DMSO-d 6 )δ 8.25(s,1H),7.92(s,1H),7.24-7.17(m,2H),7.00(d,J=7.2Hz,1H),6.89(d,J=8.0Hz,1H ),6.44(s,2H),4.14-4.10(m,1H),3.90(d,J=8.4Hz,2H),3.81(s,3H),3.24(s,6H),2.83- 2.78(m,2H),2.54(d,J=12.8Hz,3H),2.43-2.22(m,5H),2.17(d,J=7.2Hz,2H),2.15(s,3 H),1.86(d,J=12.4Hz,2H),1.77(d,J=12.0Hz,2H),1.68-1.56(m,3H),1.33-1.22(m,5H). (ESI) m / z 575.3. [M+H] + .
[0126] Refer to the method of Step 1 of Example 7, and replace 1-bromo-4-chloro-2-methoxybenzene with the starting material in the table below to prepare the corresponding intermediate, and then replace 1-methyl-4-(piperidin-4-ylmethyl)piperazine with 1-methyl-4-(4-piperidinyl)piperazine, and refer to the method of Example 7 to obtain the compound in the table below. [Table 22]
[0127] Refer to the method of Step 9 of Example 1 and the method of Step 1 of Example 2, substituting the starting material in the table below for tetrahydropyran-4-amine to prepare the corresponding intermediate, and then refer to the method of Example 7, substituting 1-methyl-4-(piperidin-4-ylmethyl)piperazine for 1-methyl-4-(4-piperidinyl)piperazine to prepare the compound in the table below. [Table 23-1] [Table 23-2] [Table 23-3]
[0128] Substituting 1-methyl-4-(piperidin-4-ylmethyl)piperazine with the starting materials in the table below and following the procedure of Example 7, the following compounds are obtained. [Table 24]
[0129] By replacing 1-((1-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yl)methyl)-4-methylpiperazine with the starting material in the following table, and following the procedure of Example 7 and the procedure of catalytic hydrogenation in Step 4 of Example 1, the compound in the following table is obtained. [Table 25]
[0130] Replace 1-((1-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yl)methyl)-4-methylpiperazine with the starting material in the table below, refer to the method in Step 2 of Example 2, and refer to the method in Step 12 of Example 1 to remove the protecting group to obtain the compound in the table below.
[0131] Substituting 1-((1-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yl)methyl)-4-methylpiperazine for the starting material in the following table and following the procedure of Example 7, the compound in the following table is obtained. [Table 27-1] [Table 27-2]
[0132] Refer to the method of Step 9 of Example 1, and replace tetrahydropyran-4-amine with starting material 2 in the following table to prepare the corresponding intermediate, then replace 1-((1-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidin-4-yl)methyl)-4-methylpiperazine with starting material 1, and refer to the method from Step 3 of Example 7 to obtain the compound in the following table. [Table 28]
[0133] Example 8: 3-Ethyl-8-(4-methylpiperazin-1-yl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (compound 53) [ka]
[0134] Step 1: To a mixture of 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (75 mg, 0.15 mmol) and 1-methylpiperazine (30 mg, 0.30 mmol) in 1,4-dioxane (5 mL), potassium t-butoxide (43 mg, 0.45 mmol), tBuXPhos Pd G3 (27 mg, 0.030 mmol), and tBuXPhos (28 mg, 0.060 mmol) are added. The mixture is reacted under nitrogen gas protection at 110 °C with stirring for 14 hours. After the reaction is complete, it is cooled to room temperature and water (10 mL) is added. The mixture is extracted three times with ethyl acetate (10 mL x 3). The organic phases are combined, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by silica gel chromatography column (dichloromethane / methanol=10:1) to give a brown oil (50 mg, 64% yield). (ESI) m / z 522.2. [M+1] + .
[0135] Step 2: Following the procedure of Step 4 of Example 7, prepare N5-(2,4-dimethoxybenzyl)-3-ethyl-8-(4-methylpiperazin-1-yl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (50 mg, 0.096 mmol) to give compound 53 as a yellow solid (15 mg, 42%). 1 H NMR (400MHz, DMSO-d 6 )δ 8.18(brs,2H),7.37(s,1H),7.05(d,J=7.2Hz,1H),6.16(brs,2H),4.25-4.19(m,1H),3.98-3.94(m,2H),3.41-3.35(m,2H),3.22 -3.06(m,2H),2.79(d,J=7.2Hz,2H),2.59-2.52(m,4H),2.28(s,3H),1.93-1.87(m,2H),1.72-1.62(m,2H),1.28(t,J=7.2Hz,4H). (ESI)m / z 373.1.[M+1] + .
[0136] Example 9: 3-((5-amino-3-ethyl-8-(1-(1'-methyl-[1,4'-bipiperidinyl]-4-yl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 134)
[0137] Referring to the method of Step 2 of Example 6, react compound 206 with the starting materials in the table below to give the compounds in the table below. [Table 29]
[0138] Example 10: Referring to the method of Step 2 of Example 6, react the starting material in the table below with compound 58 to obtain the compound in the table below. [Table 30-1] [Table 30-2] [Table 30-3]
[0139] Following the procedure of Step 2 in Example 6, compound 58 is reacted with the starting material in the table below, and then the protecting group is removed following the procedure of Step 4 in Example 7 to give the compound in the table below. [Table 31]
[0140] Following the procedure of Step 2 in Example 6, react compound 58 with the starting material in the table below, then follow the procedure of Step 12 in Example 1 to remove the protecting group, and finally follow the procedure of Step 2 in Example 6 to react with formaldehyde to obtain the compound in the table below. [Table 32]
[0141] Referring to the method of Step 2 of Example 6, react polaformaldehyde with compound 157 to give the following compound: [Table 33]
[0142] Example 11: 3-Ethyl-8-(1-(1-(pent-3-yl)piperidin-4-yl)-1H-pyrazol-4-yl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 232) [ka]
[0143] To a solution of compound 58 (100 mg, 0.20 mmol) in acetonitrile (3 mL), 3-bromopentane (360 mg, 2.4 mmol) and diisopropylethylamine (90 mg, 0.70 mmol) are added. The mixture is reacted for 16 hours with stirring in a sealed tube at 105 °C. After completion of the reaction, it is cooled to room temperature and water (10 mL) is added. The mixture is extracted three times with ethyl acetate (10 mL x 3). The organic phases are combined, the organic phase is dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The obtained residue is purified by preparative liquid chromatography to obtain the formate salt of compound 232 as a yellow solid (30 mg, 23% yield). 1 H NMR (400MHz, DMSO-d 6)δ 8.34(s,1H),8.17(brs,4H),8.01(s,1H),7.05(d,J=8.0Hz,1H),6.44(brs,2H),4.3 5-4.26(m,1H),4.17-4.09(m,1H),4.01-3.94(m,2H),3.49-3.43(m,2H),2.83-2.82( m,4H),2.46(d,J=12.0Hz,2H),2.30-2.23(m,1H),2.06(d,J=8.0Hz,2H),1.99-1.88 (m,4H),1.74-1.70(m,2H),1.52-1.45(m,2H),1.37-1.24(m,5H),0.91-0.87(m,6H). (ESI)m / z. 493.2[M+1] + .
[0144] Example 12: 3-Ethyl-8-(5-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)pyridin-2-yl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (compound 20) [ka]
[0145] Step 1: Add trisdibenzylideneacetonedipalladium (447 mg, 0.49 mmol) to a mixture of 3-iodopyridine (1.00 g, 4.88 mmol), 1-methyl-4-(4-piperidinyl)piperazine (893 mg, 4.88 mmol), Xantphos (282 mg, 0.49 mmol) and potassium t-butoxide (1.09 g, 9.76 mmol) in toluene (20 mL). The mixture is reacted under nitrogen gas protection at 108 °C with stirring for 4 hours. After completion of the reaction, cool to room temperature and add dichloromethane (20 mL) and water (20 mL). Extract the mixture three times with dichloromethane (20 mL x 3). Combine the organic phases, wash the organic phase with saturated brine (10 mL), dry over anhydrous sodium sulfate, filter and concentrate the filtrate under reduced pressure. The resulting residue is purified by silica gel chromatography column (dichloromethane / methanol=10:1 to dichloromethane / methanol / 25% aqueous ammonia=10:1:0.1) to give a yellow solid (750 mg, 59% yield). 1 H NMR (400 MHz, CDCl 3 )δ 8.30(d,J=2.8Hz,1H),8.07-8.05(m,1H),7.20-7.17(m,1H),7.15-7.12(m,1H),3.77-3.74(m,2H),2.81-2.74(m,2H),2.65 -2.60(m,4H),2.51-2.44(m,2H),2.41-2.38(m,1H),2.31(s,3H),2.19-2.06(m,2H),1.98-1.95(m,2H),1.72-1.62(m,2H).
[0146] Step 2: Under ice bath conditions, add NBS (770 mg, 4.33 mmol) in batches to a mixture of 1-methyl-4-(1-(pyridin-3-yl)piperidin-4-yl)piperazine (750 mg, 2.88 mmol) in dichloromethane (30 mL). Allow to react under stirring at 5-20° C. for 2 hours, then pour into water (20 mL). Extract the mixture with dichloromethane (20 mL×4). Combine the organic phases, wash the organic phase with saturated brine (5 mL), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. Purify the resulting residue by silica gel chromatography column (dichloromethane / methanol=20:1 to 10:1) to obtain a yellow solid (500 mg, 51% yield). 1 H NMR (400 MHz, CDCl 3 )δ 8.00(d,J=3.2Hz,1H),7.28-7.16(m,1H),7.07(dd,J=8.8,3.2Hz,1H),3.71-3.68(m,2H), 2.80-2.74(m,2H),2.63-2.36(m,9H),2.30(s,3H),1.97-1.94(m,2H),1.69-1.59(m,2H). MS Found:339.1[M+H] + .
[0147] Step 3 and 4: Referring to the method of Step 3 and Step 4 of Example 3, react 1-(1-(6-bromopyridin-3-yl)piperidin-4-yl)-4-methylpiperazine (145 mg, 0.43 mmol) with intermediate C (200 mg, 0.43 mmol) to obtain compound 20 as a yellow solid (60 mg, 26% yield for two steps). 1 H NMR (400MHz, DMSO-d 6)δ 8.46(s,1H),8.35-8.31(m,2H),7.39-7.36(m,1H),7.24-7.22(m,1H),6.82(s,2H),4.22-4.14(m,1H),3.96-3.94(m,2H),3.88 -3.85(m,2H),3.46-3.40(m,3H),3.07-2.73(m,12H),2.58(s,3H),1.94-1.91(m,4H),1.72-1.58(m,4H),1.32(t,J=7.2Hz,3H). MS Found:532.2[M+H] + .
[0148] Example 13: (1S,3R)-3-((5-amino-8-bromo-3-ethylpyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 151) [ka]
[0149] Steps 1 and 2, synthesis of intermediate D: Refer to the methods of Example 1, Step 9 and Example 2, Step 1 to prepare (1S,3R)-3-aminocyclopentanol hydrochloride to obtain intermediate D as a yellow solid (two-step yield 40%). 1 H NMR (400MHz, DMSO-d 6 )δ 8.01(s,1H),7.31-7.17(m,2H),7.07(d,J=8.0Hz,1H),6.56(s,1H),6.4 4-6.38(m,1H),5.76(s,1H),4.74(d,J=3.6Hz,1H),4.56(d,J=6.0Hz,2H) ,4.52-4.41(m,1H),3.83(s,3H),3.72(s,3H),2.83-2.77(m,2H),2.13-1 .99(m,2H),1.83-1.72(m,2H),1.68-1.56(m,2H),1.30(t,J=7.2Hz,3H). (ESI) m / z 502.0[M+H] + .
[0150] Step 3: Refer to the method of Step 12 of Example 1, using intermediate D (100 mg, 0.20 mmol) to obtain compound 151 as a yellow solid (56 mg, 79% yield). 1 H NMR (400MHz, DMSO-d 6 )δ 8.14(brs,1H),8.00(s,1H),7.43(d,J=6.8Hz,1H),6.98(brs,2H),4.76(s,1H),4.55-4.45(m,1H),4.22-4.13(m,1H),2 .81(q,J=7.2Hz,2H),2.36-2.27(m,1H),2.12-2.01(m,1H),1.87-1.73(m,2H),1.70-1.58(m,2H),1.30(t,J=7.2Hz,3H). (ESI)m / z 352.1.[M+H] + .
[0151] Example 14: Referring to the method of Step 2 of Example 2, react compound 151 with the starting material in the following table to give the corresponding compound. [Table 34-1] [Table 34-2] [Table 34-3]
[0152] Example 15: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(piperidin-4-yl)-1H-pyrrol-3-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 152) and (1S,3R)-3-((5-amino-3-ethyl-8-(1-(1-methylpiperidin-4-yl)-1H-pyrrol-3-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 153) [ka]
[0153] According to the method of Example 3, intermediate D is prepared to obtain intermediate E, and the resulting product is reacted with t-butyl 4-(3-bromo-1H-pyrrol-1-yl)piperidine-1-carboxylate. According to the method of Step 12 of Example 1, the resulting product is deprotected to obtain compound 152 as a yellow solid. According to the method of Step 2 of Example 6, compound 152 is reacted with formaldehyde to obtain compound 153 as a yellow solid.
[0154] Compound 152: 1 H NMR (400MHz, DMSO-d 6 )δ 7.68(s,1H),6.96(d,J=7.2Hz,1H),6.88(s,1H),6.49(s,2H),6.07(t,J =4.0Hz,1H),5.87(s,1H),4.77(d,J=3.6Hz,1H),4.31(d,J=6.4Hz,1H), 4.09(s,1H),3.80(s,1H),2.92(d,J=12.0Hz,2H),2.77-2.72(m,2H),2. 24(s,1H),2.00-1.90(m,1H),1.81-1.47(m,11H),1.29(t,J=7.2Hz,3H). (ESI)m / z. 422.2[M+1] + .
[0155] Compound 153: 1 H NMR (400MHz, DMSO-d 6 )δ 7.69(s,1H),7.00(d,J=7.2Hz,1H),6.90(s,1H),6.55(s,2H),6.10(t,J =4.0Hz,1H),5.90-5.89(m,1H),4.79(d,J=3.6Hz,1H),4.37-4.24(m,1H) ,4.09(d,J=4.0Hz,1H),3.80(s,1H),2.95(s,2H),2.77-2.72(m,2H),2. 30(s,3H),2.02-1.57(m,11H),1.55-1.49(m,1H),1.30(t,J=7.2Hz,3H). (ESI)m / z. 436.2[M+1] + .
[0156] Example 16: Referring to the method of Step 2 of Example 6, react the starting material in the following table with compound 154 to obtain the compound in the following table. [Table 35]
[0157] Example 17: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(1,2,2,6,6-pentamethylpiperidin-4-yl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (compound 169) [ka]
[0158] Step 1: At 0°C, triethylamine (8.9 g, 88 mmol) and methanesulfonyl chloride (2.4 g, 21 mmol) are added to a solution of 4-hydroxy-1,2,2,6,6-pentamethylpiperidine (3 g, 18 mmol) in dichloromethane (30 mL). The reaction is stirred at 25°C for 6 hours. After completion of the reaction, the mixture is quenched with saturated sodium bicarbonate solution. The mixture is extracted twice with dichloromethane (30 mL x 2). The organic phases are combined, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to give a yellow oil (74.2 g, 96% yield), which is used directly in the next step reaction. (ESI) m / z 250.2. [M+H] + .
[0159] Step 2: Sodium hydride (0.48 g, 12 mmol) is added to a solution of 4-pyrazole boronate (2.3 g, 12 mmol) in N,N-dimethylformamide (20 mL). After stirring at 25° C. for 1 hour, the product of step 1 (1,2,2,6,6-pentamethylpiperidin-4-yl) methanesulfonate (2.0 g, 8.0 mol) is added and the reaction is stirred at 110° C. for 12 hours. After cooling to room temperature, the mixture is extracted with ethyl acetate (30 mL×3). The organic phases are combined, the organic phase is dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by preparative liquid chromatography to give a yellow oil (23 mg, 1.3%). (ESI) m / z. 348.2 [M+H] + .
[0160] Steps 3 and 4: Refer to the method of Step 2 in Example 2, then refer to the method of removing the protecting group in Step 12 in Example 1, to react intermediate D (15 mg, 0.03 mmol) with the product of Step 2 (26 mg, 0.075 mmol) to give compound 169 as a yellow solid (4.5 mg, 28% yield for two steps). 1 H NMR (400MHz, DMSO-d 6 )δ 8.44(s,1H),8.20(d,J=8.0Hz,4H),8.02(s,1H),7.10(d,J=8.0Hz,1H),6. 38(s,2H),4.54-4.49(m,2H),4.25-4.20(m,1H),2.81-2.78(m,2H),2.33- 2.29(m,1H),2.25(s,3H),2.09-2.05(m,1H),2.00-1.97(m,2H),1.89-1.8 0(m,5H),1.71-1.61(m,2H),1.32-1.29(m,3H),1.16(s,6H),1.11(s,6H). (ESI)m / z. 493.3[M+H] + .
[0161] Following the procedure from Step 3 of Example 17, react the starting material in the table below with Intermediate D, and then follow the procedure from Example 11 with iodomethane to give the compound in the table below. [Table 36]
[0162] Referring to the method from Step 3 of Example 17, the starting materials in the following table are reacted to give the corresponding compounds. [Table 37]
[0163] Referring to the method from Step 2 of Example 17, the starting materials in the following table are reacted to give the corresponding compounds. [Table 38]
[0164] Refer to the method of Example 17, replacing 4-hydroxy-1,2,2,6,6-pentamethylpiperidine with the starting materials in the following table and reacting to obtain the corresponding compounds. [Table 39]
[0165] Example 18: [ka]
[0166] Step 1: Referring to the method of Step 2 of Example 2, starting from intermediate D (0.30 g, 0.60 mmol), react with tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (0.45 g, 1.2 mmol) to obtain a yellow solid (180 mg, 45% yield). (ESI) m / z 673.3. [M+H] + .
[0167] Step 2: Refer to the method of Step 12 of Example 1, starting from the product of Step 1 (0.18 g, 0.27 mmol) to obtain intermediate F as a yellow solid (80 mg, 71% yield). (ESI) m / z 423.3. [M+H] + .
[0168] Referring to the method of Step 2 of Example 6, react the starting material in the table below with intermediate F, then refer to the method of Step 12 of Example 1 to remove the protecting group, and finally refer to the method of Step 2 of Example 6 to react with poraformaldehyde to obtain the compound in the table below. [Table 40]
[0169] Referring to the method of Step 2 of Example 6, reacting the starting materials in the table below with Intermediate F gives the compounds in the table below. [Table 41-1] [Table 41-2] [Table 41-3]
[0170] Referring to the method of Example 11, react the starting materials in the table below with Intermediate F to give the corresponding compounds in the table below. [Table 42-1] [Table 42-2] [Table 42-3]
[0171] Referring to the method of Step 3 of Example 35, react the starting materials in the table below with Intermediate F to give the corresponding compounds in the table below. [Table 43]
[0172] Example 19: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(1-(2-hydroxy-2-methylpropyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 181) [ka]
[0173] A solution of intermediate F (90 mg, 0.21 mmol) and 2,2-dimethyloxirane (46 mg, 0.64 mmol) in ethanol (10 mL) was reacted with stirring at 80 °C for 12 h. After completion of the reaction, the mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by silica gel chromatography column (dichloromethane / methanol = 70%:30%) to give compound 181 as a yellow solid (65 mg, 59% yield). 1 H NMR (400MHz, DMSO-d 6 )δ 8.44(s,1H),8.20(s,1H),8.02(s,1H),7.11(d,J=7.2Hz,1H),6.37(brs, 2H),4.79(d,J=3.6Hz,1H),4.54-4.44(m,1H),4.28-4.20(m,1H),4.17-4 .05(m,2H),3.11-2.99(m,2H),2.80(q,J=7.2Hz,2H),2.38-2.21(m,5H), 2.12-1.77(m,7H),1.75-1.60(m,2H),1.31(t,J=7.2Hz,3H),1.11(s,6H). (ESI)m / z. 495.2[M+1] + .
[0174] Referring to the method of Example 19, the starting materials in the following table are reacted to give the corresponding compounds in the following table. [Table 44]
[0175] Example 20: 4-(4-(5-amino-3-ethyl-2-(((1R,3S)-3-hydroxycyclopentyl)amino)pyrido[3,4-b]pyrazin-8-yl)-1H-pyrazol-1-yl)-N-isopropylpiperazine-1-carboxamide (Compound 189) [ka]
[0176] To a solution of intermediate F (80 mg, 0.19 mmol) and triethylamine (57 mg, 0.57 mmol) in tetrahydrofuran (10 mL) is added isopropyl isocyanate (19 mg, 0.23 mmol). The mixture is reacted under stirring at 25° C. for 2 hours and concentrated under reduced pressure. The resulting residue is purified by silica gel chromatography column (dichloromethane / methanol=70%:30%) to give compound 189 as a yellow solid (38 mg, 37% yield). 1 H NMR (400MHz, DMSO-d 6 )δ 8.40(s,1H),8.17(s,1H),8.05(s,1H),7.13(d,J=6.9Hz,1H),6.47(brs,2H),6.24(d,J=7 .6Hz,1H),4.79(d,J=3.6Hz,1H),4.51-4.42(m,1H),4.38-4.28(m,1H),4.25-4.18(m,1H), 4.14-4.06(m,2H),3.77(dd,J=13.4,6.8Hz,1H),2.89-2.73(m,4H),2.27(dd,J=13.4,6.8H z,1H),2.10-1.98(m,3H),1.89-1.61(m,7H),1.30(t,J=7.2Hz,3H),1.07(d,J=6.8Hz,6H). (ESI)m / z 508.3.[M+1] + .
[0177] Example 21: 1-(4-(4-(5-amino-3-ethyl-2-(((1R,3S)-3-hydroxycyclopentyl)amino)pyrido[3,4-b]pyrazin-8-yl)-1H-pyrazol-1-yl)piperidin-1-yl)-2-methylpropan-1-one (Compound 185) [ka]
[0178] A solution of isobutyric acid (25 mg, 0.28 mmol), EDCI (109 mg, 0.57 mmol), HOBT (77 mg, 0.57 mmol) and diisopropylethylamine (147 mg, 1.1 mmol) in N,N-dimethylformamide (5 mL) is stirred at 0 °C for 30 min, and then intermediate F (80 mg, 0.19 mmol) is added. The mixture is reacted with stirring at 25 °C for 2 h, and water (20 mL) is added after the reaction is completed. The mixture is extracted three times with ethyl acetate (20 mL x 3). The organic phases are combined, the organic phase is dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The obtained residue is purified by silica gel chromatography column (dichloromethane / methanol = 95%:5%) to obtain a yellow solid compound (50 mg, 51% yield). 1 H NMR (400MHz, DMSO-d 6 )δ 8.40(s,1H),8.19(s,1H),8.06(s,1H),7.08(d,J=7.2Hz,1H),6.37(brs,2H),4.79( d,J=3.6Hz,1H),4.56-4.40(m,3H),4.25-4.17(m,1H),4.12-4.02(m,1H),3.27-3.18 (m,1H),2.96-2.89(m,1H),2.80(q,J=7.2Hz,2H),2.53-2.52(m,1H),2.31-2.22(m, 1H), 2.17-2.00 (m, 3H), 1.88-1.63 (m, 6H), 1.30 (t, J=7.2Hz, 3H), 1.06-0.99 (m, 6H). (ESI)m / z 493.3.[M+1] + .
[0179] Example 22: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(6-methylpyridin-3-yl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (compound 177) [ka]
[0180] Step 1: 4-bromopyrazole (1.0 g, 6.8 mmol), cesium carbonate (6.6 g, 21 mmol), cuprous iodide (0.13 g, 0.60 mmol) and anti-N,N-dimethylcyclohexane-1,2-diamine (0.19 g, 1.3 mmol) are added to a solution of 2-methyl-5-bromopyridine (2.3 g, 14 mmol) in N,N-dimethylformamide (20 mL). The mixture is reacted with stirring under nitrogen gas protection at 110 °C for 12 hours. After the reaction is completed, it is cooled to room temperature and water (50 mL) is added. The mixture is extracted three times with ethyl acetate (50 mL x 3). The organic phases are combined, the organic phase is dried over anhydrous sodium sulfate, filtered and the filtrate is concentrated under reduced pressure. The obtained residue is purified by silica gel chromatography column (petroleum ether / ethyl acetate = 70%:30%) to obtain a yellow oil (900 mg, yield 29%). (ESI) m / z. 238.1 [M+H] + .
[0181] Steps 2 and 3: Refer to the method of Step 6 in Example 1 and the method of Step 2 in Example 2, respectively, starting from 5-(4-bromo-1H-pyrazol-1-yl)-2-picoline to obtain a boronic ester intermediate, which is reacted with compound 151 to obtain compound 177 as a yellow solid (two-step yield 11%). 1 H NMR (400MHz, DMSO-d 6)δ 9.07(s,1H),8.94(d,J=2.8Hz,1H),8.46(s,1H),8.30(s,1H),8.12-8.09(m,1H),7 .42(d,J=8.4Hz,1H),7.23(d,J=6.8Hz,1H),6.66(s,2H),4.82(d,J=3.6Hz,1H),4.5 9-4.51(m,1H),4.24-4.18(m,1H),2.85-2.79(m,2H),2.52(s,3H),2.32-2.27(m,1 H),2.11-2.03(m,1H),1.91-1.76(m,2H),1.71-1.64(m,2H),1.32(t,J=7.2Hz,3H). LC-MS: Rt=1.051min,(ESI)m / z. 431.2[M+1] + .
[0182] Referring to the synthesis method of Example 22, the starting materials in the table below are used according to the methods in steps 1 and 2 to obtain a boronic ester intermediate, which is reacted with compound 2 in accordance with step 3 to obtain the corresponding compound in the table below. [Table 45]
[0183] Following the procedures of steps 1 and 2 of Example 22, the boronic ester intermediates are obtained, and following the procedures of steps 3 and 4 of Example 7, the corresponding compounds in the table below are obtained. [Table 46]
[0184] Following the procedures of steps 1 and 2 of Example 22, the boronic ester intermediates are obtained, and following the procedures of steps 3 and 4 of Example 17, the corresponding compounds in the table below are obtained. [Table 47-1] [Table 47-2]
[0185] Referring to the method of Example 33, Step 7, compound 278 is reacted with the starting materials in the table below to give the corresponding compounds in the table below. [Table 48]
[0186] Referring to the method of Example 22, substituting the starting material in the table below for 2-methyl-5-bromopyridine gives the corresponding compound in the table below. [Table 49-1] [Table 49-2]
[0187] Referring to the method from Step 2 of Example 22, using the starting materials in the table below, the corresponding compounds in the table below are obtained. [Table 50]
[0188] Refer to the synthesis method of compound 151, and in step 1, replace (1S,3R)-3-aminocyclopentanol hydrochloride with (1R,3R)-3-aminocyclopentanol, and react to obtain intermediate 356-A in the following table. Then, refer to the method of example 22, and replace 2-methyl-5-bromopyridine with the starting material in the following table, and react to obtain the corresponding compound in the following table, and in step 3, replace compound 151 with intermediate 356-A. [Table 51]
[0189] Example 23: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(2-methylpyrimidin-4-yl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 180) [ka]
[0190] Step 1: Sodium hydride (112 mg, 4.67 mmol) is added to a solution of 4-pyrazole boronate (498 mg, 2.6 mmol) in tetrahydrofuran (20 mL). Then 4-chloro-2-methylpyrimidine (300 mg, 2.3 mmol) is added and the mixture is reacted under stirring at 25° C. for 3 hours. After the reaction is complete, water (30 mL) is added and the mixture is extracted with ethyl acetate (30 mL×3). The organic phases are combined, the organic phase is dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue is purified by silica gel chromatography column (dichloromethane / methanol=9:1) to give a white solid (200 mg, 28% yield). (ESI) m / z. 287.2. [M+H] + .
[0191] Step 2: Referring to the method of Step 2 of Example 2, react the product of Step 1 (81 mg, 0.11 mmol) with compound 151 (50 mg, 0.14 mmol) to give compound 180 as a yellow solid (7 mg, 12% yield). 1 H NMR (400MHz, DMSO-d 6 )δ 9.55(s,1H),8.74(d,J=5.6Hz,1H),8.58(s,1H),8.43(s,1H),8.17(brs,1H) ,7.75(d,J=5.6Hz,1H),7.15(d,J=7.2Hz,1H),6.58(brs,2H),4.62-4.57(m,1 H),4.31-4.27(m,1H),2.84-2.80(m,2H),2.64(s,3H),2.40-2.35(m,1H),2. 29-2.22(m,1H),1.99-1.81(m,2H),1.79-1.66(m,2H),1.33(t,J=7.2Hz,3H). (ESI) m / z. 432.2[M+1] + .
[0192] Referring to the method of Example 23, substituting the starting material in the table below for 4-chloro-2-methylpyrimidine gives the corresponding compound in the table below. [Table 52]
[0193] Example 24: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(1-(isopropylsulfonyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrido[3,4b]pyrazin-2-yl)amino)cyclopentan-1-ol (compound 187) [ka]
[0194] Step 1: Dissolve t-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (1.0 g, 2.65 mmol) in 1,4-dioxane (5 mL), then add a solution of hydrochloric acid in 1,4-dioxane (4 M, 10 mL) and react with stirring at 25° C. for 1 hour. After completion of the reaction, concentrate under reduced pressure to obtain the compound as a white solid (650 mg, 88%). (ESI) m / z 278.2. [M+H] + .
[0195] Step 2: 2-propanesulfonyl chloride (494 mg, 3.5 mmol) is added to a solution of 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine (800 mg, 2.9 mmol) and triethylamine (876 mg, 8.7 mmol) in dichloromethane (10 mL). The mixture is reacted under stirring at 25° C. for 16 hours. After completion of the reaction, water (30 mL) is added and the mixture is extracted three times with dichloromethane (20 mL×3). The organic phases are combined, the organic phase is dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to give a yellow oil (400 mg, 95% yield). (ESI) m / z. 384.3. [M+H] + .
[0196] Steps 3 and 4: Referring to the method from Step 3 of Example 17, react the product of Step 2 (73 mg, 0.19 mmol) as starting material with Intermediate D (80 mg, 0.16 mmol) to give the formate salt of compound 187 as a yellow solid (30 mg, 43% yield for two steps). 1 H NMR (400MHz, DMSO-d 6 )δ 8.43(s,1H),8.19(s,1H),8.14(s,1H),8.07(s,1H),7.12(d,J=7.2Hz,1H),6.47(s,2H),4.79(s,1 H),4.52-4.46(m,1H),4.44-4.34(m,1H),4.28-4.16(m,1H),3.76(d,J=12.0Hz,2H),3.40(d,J=6.4 Hz,1H),3.13(t,J=12.0Hz,2H),2.83-2.77(m,2H),2.32-2.25(m,1H),2.15(d,J=12.0Hz,2H),2.0 9-1.99(m,1H),1.93-1.76(m,4H),1.73-1.61(m,2H),1.31(t,J=7.2Hz,3H),1.25(d,J=6.4Hz,6H). (ESI)m / z. 529.3[M+1] + .
[0197] Referring to the method of Example 24, the starting materials in the table below are reacted to give the corresponding boronic ester intermediates, which are reacted with compound 151 to give the compounds in the table below. [Table 53]
[0198] Referring to the method of Example 24 and substituting the starting material in the table below for 2-propanesulfonyl chloride, the compound in the table below is obtained. [Table 54]
[0199] Example 25: (S)-3-Ethyl-8-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-N2-(tetrahydrofuran-3-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 259) [ka]
[0200] Steps 1 and 2: Prepare (S)-tetrahydrofuran-3-amine by referring to the synthesis method of intermediate D to obtain intermediate G as a yellow solid (28% yield for two steps). (ESI) m / z. 488.0. [M+H] + .
[0201] Step 3: Referring to the method of Step 2 of Example 2, intermediate G (200 mg, 0.41 mmol) is reacted with tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (186 mg, 0.49 mmol) as starting material to obtain intermediate H as a yellow oil (280 mg, 94% yield). (ESI) m / z 659.3. [M+H] + .
[0202] Step 4: Referring to the method of Step 12 of Example 1, starting from intermediate H (280 mg, 0.42 mmol), compound 259 is obtained as a yellow solid (88 mg, 48% yield). 1 H NMR (400MHz, DMSO-d 6)δ 8.34(s,1H),8.18(s,1H),8.03(s,1H),7.25(d,J=5.6Hz,1H),6.39(s,1H),4.71-4.67(m,1H ),4.21-4.01(m,1H),4.04-4.00(m,1H),3.94-3.90(m,1H),3.82-3.76(m,1H),3.74-3.71(m ,1H),3.06(d,J=12.0Hz,2H),2.87-2.82(m,2H),2.68-2.59(m,2H),2.54(s,1H),2.33-2.25 (m,1H),2.14-2.06(m,1H),2.02(d,J=12.0Hz,2H),1.84-1.75(m,2H),1.31(t,J=7.2Hz,3H). (ESI)m / z. 409.2[M+1] + .
[0203] Referring to the method of Example 25, substituting starting material 1 in the table below for (S)-tetrahydrofuran-3-amine, prepare the relevant intermediate, which is then reacted with starting material 2 to give the corresponding compound. [Table 55]
[0204] Refer to the method of Example 25, replace (S)-tetrahydrofuran-3-amine with the starting material in the table below, prepare intermediate 261-A in the table below, and then refer to the method of Example 11 to react intermediate 261-A with iodomethane to obtain compound 261 in the table below. [Table 56]
[0205] Prepare the compounds in the following table by referring to the method of Example 25 and substituting the starting materials in the table below for (S)-tetrahydrofuran-3-amine. [Table 57]
[0206] Referring to the method of Step 2 of Example 6, react compound 258 with the starting materials in the table below to give the compounds in the table below. [Table 58]
[0207] Referring to the synthesis method of compound 250, the starting materials in the following table are reacted to obtain the compounds in the following table. [Table 59]
[0208] Referring to the method of Step 2 of Example 6, react compound 259 with the starting materials in the table below to give the compounds in the table below. [Table 60-1] [Table 60-2]
[0209] Referring to the synthesis method of compound 225, (S)-tetrahydrofuran-3-amine is replaced with the starting material in the table below and reacted to obtain the compound in the table below. [Table 61]
[0210] Example 26: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(1-(2-hydroxyethyl)piperidin-4-yl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 207) [ka]
[0211] Step 1: To a solution of intermediate F (50 mg, 0.10 mmol) in N,N-dimethylformamide (5 mL), t-butyl(2-iodoethoxy)dimethylsilane (71 mg, 0.25 mmol) and cesium carbonate (161 mg, 0.50 mmol) are added. The mixture is stirred at 45° C. for 12 hours. After completion of the reaction, the mixture is cooled to room temperature, water (1 mL) is added, and the mixture is concentrated under reduced pressure. The resulting residue is purified by silica gel chromatography column (dichloromethane:methanol=3:1) to give a yellow solid compound (40 mg, 41% yield). (ESI) m / z 581.3. [M+H] + .
[0212] Step 2: Starting from the product of Step 1 (40 mg, 0.070 mmol), the protecting group was removed according to the method of Step 4 of Example 7 to obtain the formate salt of compound 207 as a yellow solid (5 mg, 31% yield). 1 H NMR (400MHz, DMSO-d 6 )δ 8.42(s,1H),8.18(s,1H),8.15(brs,2H),8.05(s,1H),7.12(d,J=7.2Hz,1H) ,6.42(brs,2H),4.47-4.45(m,1H),4.19-4.15(m,2H),3.55-3.52(m,2H),3. 06-3.03(m,2H),2.80-2.75(m,2H),2.55-2.50(m,4H),2.40-2.26(m,2H),2. 14-1.92(m,6H),1.83-1.81(m,2H),1.72-1.59(m,2H),1.30(t,J=7.2Hz,3H). (ESI) m / z 467.2[M+1] + .
[0213] Following the method of Example 26, by substituting Intermediate F with the starting materials in the table below, prepare the corresponding compound in the table below. [Table 62]
[0214] Example 27: (S)-3-Ethyl-8-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)-N2-(tetrahydrofuran-3-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 230) [ka]
[0215] Prepare intermediate G (588 mg, 1.2 mmol) by referring to the method of step 12 of Example 1 to obtain intermediate I (350 mg, 86% yield) as a yellow solid compound. (ESI) m / z 338.1. [M+H] + .
[0216] Referring to the method of Step 2 of Example 2, react the starting material in the following table with compound Intermediate I to give the corresponding compound. [Table 63]
[0217] Referring to the method from Step 3 of Example 17, react the starting material in the table below with intermediate G to give the corresponding compound. [Table 64]
[0218] Example 28: 3-((5-amino-3-ethyl-8-(1-(1'-ethyl-[1,4'-bipiperidinyl]-4-yl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclohexan-1-ol (Compound 246) [ka]
[0219] Prepare intermediate J by following the method of Example 25, substituting 3-aminocyclohexanol for (S)-tetrahydrofuran-3-amine, and then prepare the formate salt of compound 246 by following the method of Example 6, Step 2.1 H NMR (400MHz, DMSO-d 6 )δ 8.47(s,1H),8.22-8.17(m,4H),8.02(s,1H),6.87(d,J=7.6Hz,1H),6.36(brs,2H),4.63-4.56(m,1H),4.16-4.13(m,1H),4.08(s ,1H),3.12-2.93(m,6H),2.80(q,J=7.2Hz,2H),2.35-2.27(m,4H),2.11-1.41(m,18H),1.29(t,J=7.2Hz,3H),1.08-1.01(m,3H). (ESI)m / z 548.3.[M+1] + .
[0220] Example 29: 3-Ethyl-8-(4-(4-(4-ethylpiperazin-1-yl)piperidin-1-yl)-3-methoxyphenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 315) [ka]
[0221] Step 1: A mixture of 1-ethyl-4-(piperidin-4-ylmethyl)piperazine (8.0 g, 40 mmol) and 1-bromo-4-chloro-2-methoxybenzene (9.6 g, 43 mmol) in 1,4-dioxane (200 mL) was treated with cesium acetate (28 g, 87 mmol) and Pd 2 (dba) 3 (4.0 g, 4.3 mmol) and BINAP (5.4 g, 8.7 mmol) are added. The mixture is reacted under nitrogen gas protection at 100° C. with stirring for 12 hours. After the reaction is completed, it is cooled to room temperature and water (100 mL) is added. The mixture is extracted three times with ethyl acetate (200 mL×3). The organic phases are combined, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The obtained residue is purified by silica gel chromatography column (dichloromethane / methanol=4:1) to give a yellow oil (7.0 g, 52% yield). (ESI) m / z 338.2 [M+H] + .
[0222] Step 2: A mixture of 1-(1-(4-chloro-2-methoxyphenyl)piperidin-4-yl)-4-ethylpiperazine (7.0 g, 21 mmol) and divaleryldiboron (7.9 g, 31 mmol) in 1,4-dioxane (100 mL) was added with potassium acetate ((5.1 g, 62 mmol), Pd 2 (dba) 3 (1.2 g, 2.1 mmol) and X-Phos (2.0 g, 4.1 mmol) are added. The mixture is reacted under nitrogen gas protection at 100° C. with stirring for 12 hours. After the reaction is completed, it is cooled to room temperature and water (100 mL) is added. The mixture is extracted three times with ethyl acetate (300 mL×3). The organic phases are combined, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The obtained residue is purified by silica gel chromatography column (dichloromethane / methanol=4:1) to obtain intermediate K (7.0 g, 79% yield) as a yellow oil. (ESI) m / z 430.3. [M+H] + .
[0223] Step 3: 8-Bromo-N-(2,4-dimethoxybenzyl)-3-ethyl-N-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (1.4 g, 3.0 mmol) and intermediate K (4.0 g, 7.97 mmol) in a mixture of 1,4-dioxane / water (8 mL, 4 / 1) were treated with cesium carbonate (2.7 g, 8.0 mmol) and Pd(dppf)Cl 2 (0.20 g, 0.20 mmol) is added. The mixture is reacted in a microwave at 100 °C under nitrogen gas protection for 1 h. After completion of the reaction, it is cooled to room temperature and water (50 mL) is added. The mixture is extracted three times with ethyl acetate (30 mL x 3). The organic phases are combined, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The obtained residue is purified by silica gel chromatography column (dichloromethane / methanol = 10:1) to give a yellow solid (900 mg, 42% yield). (ESI) m / z 725.4. [M+H] + .
[0224] Step 4: N5-(2,4-dimethoxybenzyl)-3-ethyl-8-(4-(4-(4-ethylpiperazin-1-yl)piperidin-1-yl)-3-methoxyphenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (900 mg, 1.2 mmol) in trifluoroacetic acid / dichloromethane (5 mL, 3 / 1) is stirred at 25° C. for 3 hours. After completion of the reaction, diisopropylethylamine (10 mL) is added to quench the reaction. The mixture is concentrated under reduced pressure. The resulting residue is purified by preparative liquid chromatography to give the formate salt of compound 315 as a yellow solid (255 mg, 35% yield). 1 H NMR (400MHz, DMSO-d 6 )δ 8.14(brs,1H),7.91(s,1H),7.25-7.17(m,2H),7.09(d,J=8.0Hz,1H),6.91(d,J=8.0H z,1H),6.62(brs,2H),4.14-4.10(m,1H),3.91(d,J=8.0Hz,2H),3.82(s,3H),3.48(d,J =12.0Hz,3H),3.26-3.24(m,2H),2.82-2.78(m,2H),2.61-2.51(m,6H),2.49-2.44(m,6 H),1.88-1.84(m,4H),1.64-1.60(m,4H),1.31(t,J=7.2Hz,3H),1.14(t,J=7.2Hz,3H). (ESI)m / z. 575.3[M+1] + .
[0225] Referring to the method of Example 29, replace 1-ethyl-4-(piperidin-4-ylmethyl)piperazine with the starting material in the following table and react to obtain the corresponding intermediate, which is then reacted with compound 2 according to the method of Step 3 of Example 29 to obtain the following corresponding compound. [Table 65]
[0226] Referring to the method of Example 29, replace 1-ethyl-4-(piperidin-4-ylmethyl)piperazine with starting material 1, and replace 1-bromo-4-chloro-2-methoxybenzene with starting material 2 in the following table, and react to give the corresponding compound. [Table 66]
[0227] Referring to the methods of steps 1 and 2 of Example 29, replace 1-ethyl-4-(piperidin-4-ylmethyl)piperazine with the starting materials in the following table, and react to obtain the corresponding intermediates, and then referring to the methods of steps 3 and 4 of Example 29, react with intermediate D to obtain the following corresponding compounds. [Table 67]
[0228] Referring to the method of steps 1 and 2 of Example 29, replace 1-ethyl-4-(piperidin-4-ylmethyl)piperazine with the starting materials in the following table and react to obtain the corresponding intermediate, and then referring to the method of step 3 of Example 29, react with compound 151 to obtain the following corresponding compound. [Table 68]
[0229] Referring to the methods of Step 3 and Step 4 of Example 29, the starting materials in the following table are reacted to give the corresponding compounds. [Table 69]
[0230] Referring to the method of Example 29, react intermediate K with the starting material in the following table to give the corresponding compound. [Table 70]
[0231] Example 30: (1S,3R)-3-((5-amino-3-ethylpyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 263) [ka]
[0232] Referring to the method of Example 1, Step 4, starting from compound 151 (100 mg, 0.28 mmol), compound 263 is obtained as a white solid (20 mg, 25%). 1 H NMR (400MHz, DMSO-d 6 )δ 8.14(brs,1H),7.75(d,J=6.0Hz,1H),7.01(d,J=7.2Hz,1H),6.59(d,J=6.0Hz,1H),6.51(brs,2H),4.81(s,1H),4.48-4.44(m,1H),4. 19-4.17(m,1H),2.78-2.73(m,2H),2.18-2.14(m,1H),2.01-1.96(m,1H),1.80-1.74(m,2H),1.66-1.59(m,2H),1.28(t,J=7.2Hz,3H). (ESI)m / z. 274.1[M+1] + .
[0233] Example 31: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(5-methylpyrimidin-4-yl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 269) [ka]
[0234] Step 1: 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (906 mg, 4.6 mmol) and cesium carbonate (2.3 g, 7.0 mmol) are added to a solution of 4-chloro-5-methylpyrimidine (300 mg, 2.3 mmol) in N,N-dimethylformamide (15 mL). The mixture is reacted for 12 hours under stirring at 80° C. under nitrogen gas protection. After the reaction is completed, it is cooled to room temperature and water (50 mL) is added. The mixture is extracted three times with ethyl acetate (50 mL×3). The organic phases are combined, the organic phase is dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain the product (200 mg, 30% yield), which is used directly in the next step reaction. (ESI) m / z. 287.2 [M+H] + .
[0235] Steps 2 and 3: Refer to the methods of Steps 3 and 4 of Example 29, react the product of Step 1 with Intermediate D to give the formate salt of compound 269 as a yellow solid (two-step yield 46%). 1 H NMR (400MHz, DMSO-d 6 )δ 9.61(s,1H),8.90(s,1H),8.77(s,1H),8.56(s,1H),8.38(s,1H),8.14(br s,1H),7.37(d,J=7.2Hz,1H),6.91(s,2H),4.80(s,1H),4.57-4.53(m,1H), 4.30-4.25(m,1H),2.86-2.81(m,2H),2.66(s,3H),2.46-2.40(m,2H),2.23 -2.13(m,1H),1.93-1.83(m,2H),1.74-1.64(m,2H),1.32(t,J=7.2Hz,3H). (ESI)m / z. 432.2[M+1] + .
[0236] Referring to the method of Example 31, replace 4-chloro-5-methylpyrimidine with the starting material in the table below, react and separate the two isomers in the product of Step 1 to obtain the corresponding compounds in the table below. [Table 71]
[0237] Referring to the method of Example 6, Step 2, the starting materials in the following table are reacted to give the corresponding compounds in the following table. [Table 72]
[0238] Referring to the method of Example 31, replace 4-chloro-5-methylpyrimidine with the starting material in the table below and react to give the corresponding compound in the table below. [Table 73]
[0239] Referring to the method of Step 1 of Example 31, replacing 4-chloro-5-methylpyrimidine with the starting material in the table below, a boronic ester intermediate is obtained, which is reacted with compound 151 in accordance with the method of Step 2 of Example 2 to obtain the corresponding compound in the table below. [Table 74-1] [Table 74-2] [Table 74-3]
[0240] Referring to the method of Example 22, substituting the starting material in the table below for 2-methyl-5-bromopyridine, a boronic ester intermediate is obtained, which is reacted with intermediate D referring to the method of steps 2 and 3 of Example 31 to obtain the corresponding compound in the table below. [Table 75-1] [Table 75-2]
[0241] Refer to the method of Step 1 of Example 23, substituting the starting materials in the table below for 4-chloro-2-methylpyrimidine to obtain intermediate 335-A, which is then reacted with intermediate D to obtain the corresponding compound in the table below, refer to the method of Steps 2 and 3 of Example 31. [Table 76]
[0242] Referring to the method of Step 1 of Example 23, substituting the starting materials in the table below for 4-chloro-2-methylpyrimidine, intermediate 346-A is obtained, which is then reacted referring to the method of Steps 3 and 4 of Example 7 to obtain the corresponding compounds in the table below. [Table 77]
[0243] Example 32: 8-Bromo-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 2) [ka]
[0244] Referring to the method of step 12 of Example 1, starting from 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (1.0 g, 2.0 mmol), compound 2 was obtained as a yellow solid (650 mg, 93% yield). (ESI) m / z 352.0. [M+H] + .
[0245] Referring to the method of Example 23, react compound 2 with the starting material in the table below to give the corresponding compound in the table below. [Table 78]
[0246] Example 33: 3-Ethyl-8-(3-methoxy-4-(4-(8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (compound 293) and 8-(4-(4-(3,8-diazabicyclo[3.2.1]octan-3-yl)piperidin-1-yl)-3-methoxyphenyl)-3-ethyl-N2-(tetrahydro-2H-pyran-pyridin-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (compound 319) [ka]
[0247] Steps 1 and 2: Refer to the method of Steps 1 and 2 of Example 1, starting with tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (3.5 g, 0.016 mol) and 4-oxopiperidine-1-carboxylic acid benzyl ester (5.7 g, 0.025 mol) to obtain a yellow oil (3 g, 61% yield for two steps). (ESI) m / z 296.3. [M+H] + .
[0248] Steps 3 and 4: Refer to the method of Steps 1 and 2 of Example 7, starting from t-butyl 3-(piperidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate to obtain intermediate 293-A as a brown oil (2-step yield 66%). (ESI) m / z 528.3. [M+H] + .
[0249] Steps 5 and 6: Referring to the synthesis method of compound 8 in Example 2, intermediate 293-A is reacted with 8-bromo-N5-(2,4-dimethoxybenzyl)-3-ethyl-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine to obtain compound 319 as a yellow solid (two-step yield 35%). 1 H NMR (400MHz, DMSO-d 6)δ 8.31(s,2H),7.92(s,1H),7.22-7.18(m,2H),7.01(d,J=7.2Hz,1H),6.89(d,J=8.4H) z,1H),6.45(s,2H),4.17-4.07(m,1H),3.92-3.88(m,2H),3.81(s,3H),3.77(s,2H) ,3.41(d,J=11.6Hz,3H),3.27(t,J=11.2Hz,3H),2.83-2.74(m,4H),2.60-2.54(m,2 H),2.32-2.29(m,1H),1.88-1.75(m,8H),1.66-1.54(m,4H),1.31(t,J=7.2Hz,3H). (ESI)m / z. 573.3[M+1] + .
[0250] Step 7: Compound 319 (100 mg, 0.17 mmol) and formaldehyde (8.0 mg, 0.27 mmol) in methanol (10 mL) are stirred at 25° C. for 10 minutes, and then sodium borohydride (20 mg, 0.52 mmol) is added. The mixture is stirred at 25° C. for 30 minutes and then concentrated under reduced pressure. The resulting residue is purified by silica gel chromatography column (dichloromethane / methanol=1:1) to give compound 293 (40 mg, 39% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d 6 )δ 7.92(s,1H),7.27-7.12(m,2H),7.00(d,J=7.2Hz,1H),6.88(d,J=8.0Hz,1H),6.44(br s,2H),4.19-4.01(m,1H),3.92-3.88(m,2H),3.88(s,3H),3.39(d,J=12.0Hz,2H),3.30 -3.22(m,2H),3.10(s,2H),2.83-2.78(m,2H),2.66-2.54(m,4H),2.38(d,J=8.0Hz,2H ),2.22(d,J=12.0Hz,4H),1.87-1.77(m,6H),1.70-1.50(m,6H),1.31(t,J=7.2Hz,3H). (ESI)m / z. 587.3[M+1] + .
[0251] Example 34: (1S,3R)-3-((5-amino-3-ethyl-8-(3-methoxy-4-(1-(1-methylpiperidin-4-yl)-1H-pyrazol-4-yl)phenyl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (compound 312) [ka]
[0252] Step 1: A mixture of tert-butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate (2.0 g, 5.0 mmol) and 1-bromo-4-chloro-2-methoxybenzene (1.8 g, 7.0 mmol) in tetrahydrofuran / water (50 mL) was treated with cesium carbonate (5.18 g, 15.0 mmol) and Pd(dppf)Cl. 2 (0.39 g, 0.50 mmol) is added. The mixture is reacted under nitrogen gas protection at 70° C. with stirring for 1 hour. After the reaction is complete, it is cooled to room temperature and water (20 mL) is added. The mixture is extracted three times with ethyl acetate (10 mL×3). The organic phases are combined, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The obtained residue is purified by silica gel chromatography column (petroleum ether / ethyl acetate=70% / 30%) to obtain a yellow oil (1.8 g, 83% yield). (ESI) m / z. 392.1 [M+H] + .
[0253] Steps 2 to 5: Refer to the method of steps 4 to 7 of Example 33, and react the product of step 1 to obtain the formate salt of compound 312 as a yellow solid (four-step yield 1.3%). 1 H NMR (400MHz, DMSO-d 6)δ 8.18(d,J=4.0Hz,3H),8.00(s,1H),7.94(s,1H),7.60(d,J=8.0Hz,1H),7.43(d, J=1.2Hz,1H),7.31-7.29(m,1H),7.05(d,J=7.2Hz,1H),6.53(s,2H),4.44-4.39 (m,1H),4.20-4.09(m,2H),3.91(s,3H),2.89(s,2H),2.79(m,2H),2.24(s,3H), 2.19-1.98(m,7H),1.96-1.91(m,1H),1.84-1.54(m,5H),1.31(t,J=7.2Hz,3H). (ESI)m / z. 543.3.[M+H] + .
[0254] Example 35: 3-Ethyl-8-(3-methoxy-4-(3-methyl-4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 287) [ka]
[0255] Step 1: Refer to the method of Step 2 of Example 6, starting from 1-methylpiperazine (1.5 g, 15 mmol) and N-Boc-3-methyl-4-piperidone (3.2 g, 15 mmol) to obtain intermediate 287-A as a white solid (2.5 g, 53% yield). (ESI) m / z. 298.3 [M+1] + .
[0256] Step 2: Refer to the method of Step 4 of Example 7, starting from intermediate 287-A (2.5 g, 8.0 mmol) to obtain intermediate 287-B (1.7 g, 87% yield) as a white solid. (ESI) m / z. 198.3 [M+1] + .
[0257] Step 3: To a mixture of intermediate 287-B (300 mg, 1.5 mmol) and 1-bromo-4-chloro-2-methoxybenzene (336 mg, 1.5 mmol) in 1,4-dioxane (10 mL), potassium t-butoxide (438 mg, 4.6 mmol), tBuXPhos Pd G3 (120 mg, 0.15 mmol), tBuXPhos (129 mg, 0.30 mmol) are added. The mixture is reacted with stirring for 1 h under nitrogen gas protection and microwave conditions at 100 °C. After completion of the reaction, it is cooled to room temperature and water (30 mL) is added. The mixture is extracted three times with ethyl acetate (30 mL x 3). The organic phases are combined, dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography column (dichloromethane / methanol=70%:30%) to give intermediate 287-C as a yellow oil (280 mg, 54% yield). (ESI) m / z 338.2. [M+1] + .
[0258] Steps 4 and 5: Referring to the method of Step 2 of Example 7, intermediate 287-C is reacted to obtain intermediate 287-D, and then referring to the method of Step 2 of Example 2, intermediate 287-D is reacted with compound 2 to obtain a formate salt of compound 287 as a yellow solid (two-step yield: 37%). 1 H NMR (400MHz, DMSO-d 6 )δ 8.14(brs,1H),7.91(s,1H),7.22-7.20(m,2H),7.05(d,J=7.2Hz,1H),6.88-6.85(m, 1H),6.55(s,2H),4.14-4.10(m,1H),3.92-3.89(m,2H),3.82(s,3H),3.41-3.37(m,5 H),3.30-3.24(m,5H),2.84-2.78(m,3H),2.54-2.52(m,2H),2.51(s,3H),2.17(s,3H) ),1.88-1.84(m,3H),1.63-1.57(m,3H),1.31(t,J=7.2Hz,3H),1.09(d,J=6.8Hz,3H). (ESI)m / z. 575.3[M+1] + .
[0259] Example 36: (1S,3R)-3-((5-amino-3-ethyl-8-(3-methoxy-4-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 286) [ka]
[0260] Step 1: Refer to the method of Step 1 of Example 7, and react with t-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (1.1 g, 5.2 mmol) to obtain intermediate 286-A as a yellow oil (0.97 g, 50% yield). (ESI) m / z. 353.3 [M+1] + .
[0261] Step 2: Refer to the method of Step 4 of Example 7, starting from intermediate 286-A (970 mg, 2.7 mmol), to obtain intermediate 287-B as a white solid (450 mg, 65% yield). (ESI) m / z. 253.1 [M+1] + .
[0262] Step 3: Refer to the method of Step 7 of Example 33, starting from intermediate 286-B (450 mg, 1.8 mmol) to obtain intermediate 286-C as a white solid (370 mg, 74% yield). (ESI) m / z 267.1. [M+H] + .
[0263] Steps 4 and 5: Referring to the method of Step 2 of Example 7, intermediate 286-C is reacted to obtain intermediate 286-D, and then referring to the method of Step 2 of Example 2, intermediate 286-D is reacted with compound 151 to obtain compound 286 as a yellow solid (two-step yield: 2.8%). 1 H NMR (400MHz, DMSO-d 6))δ 7.90(s,1H),7.32(d,J=1.6Hz,1H),7.19-7.16(m,1H),7.00(d,J=7.2Hz,1H),6. 81(d,J=8.4Hz,1H),6.41(s,2H),4.75(d,J=3.6Hz,1H),4.42-4.37(m,1H),4.13( d,J=4.4Hz,1H),3.81(s,3H),3.21-3.06(m,4H),2.85-2.72(m,4H),2.21(s,3H) ,2.16-2.11(m,1H),1.96-1.81(m,5H),1.77-1.54(m,4H),1.30(t,J=7.2Hz,3H). (ESI)m / z. 504.3.[M+H] + .
[0264] Example 37: 3-Ethyl-8-(3-methoxy-4-(4-(3-methyl-3,8-diazabicyclo[3.2.1]octan-8-yl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrido[3,4-b]pyrazine-2,5-diamine (Compound 327) [ka]
[0265] Step 1 to Step 3: Refer to the method of Step 1 to Step 3 of Example 7, and react with 1,4-dioxa-8-azaspiro[4.5]decane to obtain intermediate 327-A as a yellow solid (three-step yield 20%). (ESI) m / z. 671.3 [M+1] + .
[0266] Step 4: A solution of intermediate 327-A (1.0 g, 1.5 mmol) in trifluoroacetic acid / dichloromethane (1 mL / 10 mL) is stirred at 25° C. for 1.5 hours. After completion of the reaction, the mixture is concentrated under reduced pressure, and the resulting residue is purified by silica gel chromatography column (1% aqueous ammonia / dichloromethane=30% / 70%) to obtain intermediate 327-B (750 mg, 92% yield) as a yellow solid. (ESI) m / z. [M+H] + 521.4.
[0267] Step 5: To a solution of intermediate 327-B (600 mg, 1.2 mmol) in 6N hydrochloric acid (6 mL), add acetic acid (3 mL) and then stir at 70° C. for 3 hours. After the reaction is completed, concentrate under reduced pressure, make an alkaline solution of ammonia in methanol (20 mL) and concentrate under reduced pressure. The resulting residue is purified by silica gel chromatography column (1% aqueous ammonia in methanol / dichloromethane=30% / 70%) to obtain intermediate L as a yellow solid (350 mg, 32% yield). (ESI) m / z. [M+H] + 477.2.
[0268] Step 6: To a mixture of intermediate L (150 mg, 0.30 mmol) and 3-methyl-3,8-diazabicyclo[3.2.1]octane (79 mg, 0.60 mmol) in 1,2-dichloroethane (20 mL) is added sodium triacetoxyborohydride (200 mg, 0.90 mmol). The mixture is stirred at 80° C. for 16 hours, cooled to room temperature after completion of the reaction, and then concentrated under reduced pressure. The resulting residue is purified by preparative liquid chromatography to give the formate salt of compound 327 as a yellow solid (17 mg, 9% yield). 1 H NMR (400MHz, DMSO-d 6 )δ 8.20(brs,1.8H),7.92(s,1H),7.26-7.17(m,2H),7.01(d,J=7.2Hz,1H),6.89(d,J=8.0Hz,1H),6. 45(brs,2H),4.14-4.10(m,1H),3.91(d,J=8.4Hz,2H),3.82(s,3H),3.48(s,4H),3.25-3.20(m,2H ),2.80(t,J=7.2Hz,2H),2.64-2.52(m,4H),2.48-2.41(m,4H),2.22(d,J=12.0Hz,2H),1.96(d,J= 12.0Hz, 2H), 1.86 (d, J = 12.4Hz, 2H), 1.75-1.57 (m, 6H), 1.50-1.39 (m, 2H), 1.31 (t, J = 7.2Hz, 3H). (ESI)m / z. 587.4[M+H] + .
[0269] Referring to the reductive amination method of Step 6 of Example 37, the starting material in the table below is reacted with intermediate L to give the corresponding compound in the table below. [Table 79]
[0270] Example 38: 3-Ethyl-8-(3-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)-N2-(tetrahydro-2H-pyran-4-yl)-1,6-naphthyridine-2,5-diamine (Compound 113) [ka]
[0271] Synthesis of intermediate M: Refer to the synthesis method of steps 1 and 2 of Example 7, and react with 1-methyl-4-(4-piperidinyl)piperazine (5.0 g, 30 mmol) to obtain intermediate M as a yellow solid (two-step yield 24%). 1 H NMR (400 MHz, CDCl 3 )δ 7.39(d,J=8.0Hz,1H),7.25(s,1H),6.92(d,J=8.0Hz,1H),3.90(s,3H),2.51-2.34(m,13H),2.34(s,3H),1.89-1.76(m,4H),1.33(s,12H). (ESI)m / z. [M+1] + 416.2.
[0272] Step 1: Add NBS (260 mg, 1.5 mmol) to a solution of 4-amino-2-chloropyridine-3-formaldehyde (200 mg, 1.3 mmol) in N,N-dimethylformamide (5 mL). Allow to react for 5 hours under stirring at 25° C., then pour into water (10 mL). The solid precipitates, is filtered, and dried to give intermediate 113-A (215 mg, 72% yield) as a white solid. 1 H NMR (400 MHz, CDCl 3)δ 10.39(brs,1H),9.24(s,1H),8.24(s,1H),5.73(s,1H). (ESI)m / z 234.9[M+H] +
[0273] Step 2: At -78°C, add LDA solution (1.9mL, 3.8mmol, 2mol / L) to a solution of ethyl butyrate (440mg, 3.8mmol) in tetrahydrofuran (10mL). React for 1 hour under stirring at -78°C, then add intermediate 113-A (0.21g, 0.90mmol). React for 14 hours under stirring at 25°C. Add saturated ammonium chloride solution (10mL). Extract the mixture three times with ethyl acetate (10mL x 3). Combine the organic phases, dry the organic phase over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. Purify the resulting residue by silica gel chromatography column (petroleum ether / ethyl acetate = 10:1) to obtain intermediate 113-B as a white solid (88mg, 40% yield). 1 H NMR (400MHz, DMSO-d 6 )δ 11.51(brs,1H),8.50(s,1H),7.85(s,1H),2.59(dd,J=14.8,7.2Hz,2H),1.19(t,J=7.2Hz,3H). (ESI)m / z 286.9[M+H] + .
[0274] Step 3: Refer to the method of Step 1 of Example 2, starting from intermediate 113-B (88 mg, 0.31 mmol), to obtain intermediate 113-C as a pale yellow solid (80 mg, 62% yield). (ESI) m / z 418.0 [M+H] + .
[0275] Step 4: Referring to the method of Step 8 of Example 1, starting from intermediate 113-C (80 mg, 0.19 mmol), intermediate 113-D was obtained as a brown solid (90 mg, the crude product was used directly in the next step reaction).
[0276] Step 5: A mixture of intermediate 113-D (90 mg) and tetrahydropyran-4-amine (412 mg, 4.1 mmol) is reacted with stirring at 145° C. for 1 hour. After completion of the reaction, it is cooled to room temperature and concentrated under reduced pressure, and the resulting residue is purified by silica gel chromatography column (petroleum ether / ethyl acetate=1:1) to obtain intermediate 113-E (60 mg, 89% yield) as a brown solid. (ESI) m / z 353.0 [M+H] + .
[0277] Step 6: Referring to the method of Step 2 of Example 2, react intermediate 113-E (60 mg, 0.17 mmol) and intermediate M (142 mg, 0.34 mmol) as starting materials to obtain compound 113 formate salt as a yellow solid (23 mg, 23% yield). 1 H NMR (400MHz, DMSO-d 6 )δ 8.20(brs,3H),8.00(s,1H),7.81(s,1H),7.23-7.13(m,2H),6.88(d,J=8.0Hz,1H),6.75(s ,2H),6.45(d,J=7.2Hz,1H),4.19-4.11(m,1H),3.92-3.84(m,2H),3.84-3.77(m,3H),3.45 (d,J=11.2Hz,2H),3.23(t,J=11.2Hz,2H),2.62-2.54(m,6H),2.53-2.51(m,1H),2.48-2.2 0(m,2H),2.22(s,3H),1.90-1.76(m,4H),1.65-1.48(m,4H),1.25(dd,J=12.0,4.8Hz,3H). (ESI)m / z. 560.3[M+1] + .
[0278] Referring to the synthesis method of Step 6 of Example 38, the starting material in the following table is reacted with intermediate M to obtain the corresponding compound in the following table. [Table 80]
[0279] Example 39: 3-Ethyl-8-(3-methoxyphenyl)-N2-(tetrahydro-2H-pyran-4-yl)pyrazino[2,3-d]pyridazine-2,5-diamine (Compound 116) [ka]
[0280] Step 1: Add iron powder (12 g, 0.21 mol) to a solution of 3,6-dichloro-5-nitropyridazin-4-amine (4.4 g, 21 mmol) in ethanol (40 mL) and saturated ammonium chloride (40 mL). Allow to react for 18 hours under stirring at 25°C, filter, and wash the filter cake with ethanol (40 mL). Remove ethanol from the filtrate and extract the residue three times with ethyl acetate (100 mL x 3). Combine the organic phases, dry the organic phase over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. Purify the resulting residue by silica gel chromatography column (dichloromethane:methanol = 20:1) to obtain intermediate 116-A as a yellow solid (1.8 g, 43% yield). (ESI) m / z 178.9 [M+H] + .
[0281] Step 2 to Step 4: Refer to the method of Step 7 to Step 9 of Example 1, and react the intermediate 116-A to obtain the intermediate 116-D as a white solid (three-step yield 2.2%). (ESI) m / z 312.1 [M+H] + .
[0282] Step 5: Refer to the method of Step 1 of Example 8, and react intermediate 116-D (66 mg, 0.21 mmol) to obtain intermediate 116-E (60 mg, 61% yield) as a yellow solid. (ESI) m / z 441.1 [M+H] + .
[0283] Step 6: Refer to the method of Step 1 of Example 17, react intermediate 116-E (50 mg, 0.12 mmol) with trifluoromethanesulfonic anhydride (40 mg, 0.14 mmol) to obtain intermediate 116-E as a yellow solid (50 mg, 65% yield). (ESI) m / z 573.0 [M+H] + .
[0284] Step 7 and Step 8: Referring to the method of Step 3 and Step 4 of Example 17, react intermediate 116-E (70 mg, 0.12 mmol) with (3-methoxyphenyl)boronic acid (37 mg, 0.24 mmol) to give the formate salt of compound 116 as a white solid (5 mg, 11% yield for two steps). 1 H NMR (400MHz, DMSO-d 6 )δ 8.23(s,1H),7.73-7.71(m,2H),7.41(d,J=7.2Hz,1H),7.38-7.34(m,1H),7.00-6.97(m,1H),6.70(s,2H),4.16-4.12(m,1H), 3.96-3.92(m,2H),3.82(s,3H),3.42(s,2H),2.90-2.84(m,2H),1.89(d,J=12.0Hz,2H),1.67-1.61(m,2H),1.35-1.31(m,3H). (ESI)m / z. 381.1[M+1] + .
[0285] Referring to the synthetic method of Example 39, in step 7, replace m-methoxyphenylboronic acid with intermediate M and react to give the compounds in the following table. [Table 81]
[0286] Example 40: (1S,3R)-3-((5-amino-3-ethyl-8-(3-methoxy-4-(2-methylpyrimidin-4-yl)phenyl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 288) [ka]
[0287] Step 1: Referring to the method of Step 2 of Example 2, react 4-chloro-2-methylpyrimidine (1.0 g, 7.8 mmol) with (4-chloro-2-methoxyphenyl)boronic acid (1.7 g, 9.3 mmol) to obtain intermediate 288-A as a brown solid (1.6 g, 87% yield).
[0288] Steps 2 and 3: Refer to the method of Step 2 of Example 7, react intermediate 288-A to obtain intermediate, and then refer to the method of Step 2 of Example 2, react compound 151 to obtain compound 288 formate salt as a yellow solid (two-step yield about 59%). 1 H NMR (400MHz, DMSO-d 6 )δ 8.67(d,J=5.6Hz,1H),8.14(brs,1H),8.07(s,1H),8.01(d,J=8.4Hz,1H),7.87(d,J=5.6H z,1H),7.58-7.54(m,1H),7.51-7.47(m,1H),7.16(d,J=7.2Hz,1H),6.81(brs,2H),4.87- 4.65(m,1H),4.46-4.38(m,1H),4.17-4.09(m,1H),3.94(s,3H),2.81(q,J=7.2Hz,2H),2. 67(s,3H),2.20-2.11(m,1H),1.97-1.88(m,1H),1.82-1.58(m,4H),1.32(t,J=7.2Hz,3H). (ESI)m / z 472.2.[M+1] + .
[0289] Referring to the methods of Step 1 and Step 2 of Example 40, the starting materials in the table below are reacted to give the boronic ester intermediates, and then referring to the method of synthesis of compound 8 from Step 2 of the Example, intermediate D is reacted to give the corresponding compounds in the table below. [Table 82]
[0290] Example 41: Cis and trans 4-(4-(5-amino-3-ethyl-2-(((1R,3S)-3-hydroxycyclopentyl)amino)pyrido[3,4-b]pyrazin-8-yl)-1H-pyrazol-1-yl)-1-methylcyclohexan-1-ol (Compounds 284 and 285) Compounds 284 and 285 are obtained by reacting the cis and trans starting materials, respectively, in the following route. [ka]
[0291] Step 1: Under 0°C conditions, isopropylmagnesium chloride (about 5 equivalents) is added dropwise to a solution of cis or trans 4-(4-iodo-1H-pyrazol-1-yl)-1-methylcyclohexan-1-ol in tetrahydrofuran. The mixture is reacted under nitrogen gas protection at 0°C with stirring for 1 hour, and then 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (about 5.5 equivalents) is added. The mixture is reacted under nitrogen gas protection at 0°C with stirring for 1 hour, and then the temperature is raised to 25°C and the mixture is reacted under stirring for 3 hours. After the reaction is completed, the mixture is concentrated under reduced pressure, and the resulting residue is purified by silica gel chromatography column (petroleum ether:ethyl acetate=3:7 to ethyl acetate) to obtain intermediate N as a colorless oil (yield about 72%). (ESI) m / z. 307.2. [M+H] + .
[0292] Steps 2 and 3: Refer to the method of steps 2 and 3 of Example 31, and react intermediate N with intermediate D to obtain compound 284 (two-step yield 30%) and compound 285 (two-step yield 6.5%), all as yellow solids. Compound 284: 1 H NMR (400MHz, DMSO-d 6)δ 8.45(s,1H),8.17-8.13(m,2H),8.01(s,1H),7.28(d,J=6.8Hz,1H),6.82 (s,2H),4.92-4.65(m,1H),4.54-4.46(m,1H),4.26-4.07(m,3H),2.82(q ,J=7.2Hz,2H),2.34-2.27(m,1H),2.12-2.03(m,3H),1.88-1.80(m,4H), 1.71-1.63(m,4H),1.53-1.46(m,2H),1.31(t,J=7.2Hz,3H),1.16(s,3H). (ESI) m / z 452.3.[M+1] + . Compound 285: 1 H NMR (400MHz, DMSO-d 6 )δ 8.43(s,1H),8.19(s,2H),8.02(s,1H),7.10(d,J=7.2Hz,1H),6.38(brs,2H),4.50-4.47(m,1H),4.28-4.11(m,2H), 2.80(q,J=7.2Hz,2H),2.35-2.25(m,1H),2.05-2.00(m,3H),2.00-1.52(m,11H),1.30(t,J=7.2Hz,3H),1.19(s,3H). (ESI)m / z. 452.3[M+1] + .
[0293] Example 42: (1S,3R)-3-((5-amino-3-ethyl-8-(1-(4-((1-methylpiperidin-4-yl)oxy)phenyl)-1H-pyrazol-4-yl)pyrido[3,4-b]pyrazin-2-yl)amino)cyclopentan-1-ol (Compound 292) [ka]
[0294] Step 1: Refer to the method of Step 1 of Example 22, react 4-(4-iodophenoxy)-1-methylpiperidine (800 mg, 2.5 mmol) with 4-bromo-1H-pyrazole (389 mg, 2.6 mmol) to obtain intermediate 292-A as a yellow solid (410 mg, 48%). (ESI) m / z 336.1 [M+H] + .
[0295] Step 2: Under nitrogen gas protection at -78°C, add n-butyl group solution (0.5mL, 2.4N) dropwise to a solution of intermediate 292-A (350mg, 1.04mmol) in tetrahydrofuran (10mL), then react with stirring for 20 minutes, and add a solution of 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (328mg, 2.08mmol) in tetrahydrofuran (5mL). Under nitrogen gas protection at -78°C, react the mixture with stirring for 1 hour, then warm to 0°C and react with stirring for 1 hour. After the reaction is completed, add 2mL of methanol to quench, concentrate under reduced pressure, and the obtained residue is purified by silica gel chromatography column (dichloromethane:methanol=9:1) to obtain intermediate 292-B as a yellow oil (150mg, 86% yield). (ESI) m / z. 302.2.[M+H] + .
[0296] Steps 3 and 4: Referring to the method of Steps 2 and 3 of Example 31, react intermediate 292-B (114 mg, 0.398 mmol) with intermediate D (100 mg, 0.199 mmol) to give the formate salt of compound 292 as a yellow solid (38 mg, two-step yield 3.9%). 1 H NMR (400MHz, DMSO-d 6 )δ 7.77-7.70(m,2H),7.22-7.15(m,4H),6.91(d,J=8.8Hz,2H),6.52(d,J =1.6Hz,1H),4.72-4.68(m,1H),4.60-4.54(m,1H),4.09(s,1H),4.00-3 .96(m,1H),3.34-3.20(m,4H),2.79(s,3H),2.73-2.66(m,2H),2.14-1. 85(m,5H),1.76-1.53(m,5H),1.48-1.38(m,1H),1.25(t,J=7.2Hz,3H). (ESI)m / z. 529.3.[M+H] + .
[0297] Example 43: (S,E)-N-(1-((2-((4-(5-amino-3-ethyl-2-((tetrahydro-2H-pyran-4-yl)amino)pyrido[3,4b]pyrazin-8-yl)-2-methoxyphenyl)amino)ethyl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide (compound 358) [ka]
[0298] Step 1: Refer to the method of Step 2 of Example 6, react 4-bromo-2-methoxyaniline (8.0 g, 39 mmol) with t-butyl (2-oxyethyl)carbamate (6.6 g, 41 mmol) to obtain intermediate 358-A as a yellow solid (4.5 g, 30%). (ESI) m / z 346.1 [M+H] + .
[0299] Steps 2 to 4: Refer to the method of steps 2 to 4 of Example 7, and react intermediate 358-A to obtain intermediate 358-B as a yellow solid (three-step yield 23%). (ESI) m / z. 438.2. [M+H] + .
[0300] Step 5: (E)-4-(dimethylamino)but-2-enoic acid (500 mg, 3.9 mmol) and (2S)-2-(methylamino)propanoic acid t-butyl ester (678 mg, 4.3 mmol) are added to a dichloromethane solution (10 mL) of HATU (1.9 g, 5.0 mmol) and triethylamine (0.77 g, 7.7 mmol). The mixture is reacted under stirring at 25° C. for 4 hours, and after completion of the reaction, it is concentrated under reduced pressure. The obtained residue is purified by silica gel chromatography column (methanol (containing 1% aqueous ammonia) / dichloromethane = 0% to 100% within 20 minutes) to obtain intermediate 358-C as a yellow solid (980 mg, 84% yield). (ESI) m / z. 271.1. [M+H] + .
[0301] Step 6: Refer to the method of Step 1 of Example 24, react intermediate 358-C (500 mg, 1.9 mmol) to give intermediate 358-D as a yellow solid (350 mg, 88% yield). (ESI) m / z. 215.1. [M+H] + .
[0302] Step 7: Referring to the method of Step 1 of this example, react intermediate 358-D (62 mg, 0.29 mmol) with intermediate 358-B (120 mg, 0.27 mmol) to give compound 358 as a yellow solid (18.5 mg, 11% yield). 1 H NMR (400MHz, DMSO-d 6 )δ 8.17(s,2H),7.98(s,1H),7.88(s,1H),7.15(d,J=6.0Hz,2H),6.98(d,J=7.2Hz,1H),6.67-6.59(m ,2H),6.52(s,1H),6.42(s,2H),5.04-5.00(m,2H),4.22-4.11(m,1H),3.96-3.87(m,2H),3.81(s, 3H),3.31-3.28(m,3H),3.16-3.12(m,2H),3.10-3.00(m,2H),2.90(s,2H),2.80-2.75(m,3H),2.1 6-2.10(m,6H),1.87-1.84(m,2H),1.63-1.60(m,2H),1.31(t,J=7.2Hz,1H),1.23(d,J=7.2Hz,1H). (ESI)m / z. 634.3.[M+H] + .
[0303] Biological Test Example 1. In vitro inhibitory activity experiment of FLT3 kinase: Reagents and Consumables [Table 83]
[0304] device Centrifuge (Manufacturer: Eppendorf, Model: 5430), Microplate reader (Manufacturer: Perkin Elmer, Model: Caliper EZ ReaderII), Echo 550 (Manufacturer: Labcyte, Model: Echo 550)
[0305] Experimental Method 1. Kinase reaction process (1) Prepare 1× Kinase buffer. (2) Preparation of compound concentration gradient: The initial concentration of the test compound is 1 μM, diluted 3 times, 10 concentrations, and detected in one well. Serially dilute 10 different concentrations of the solution with 100 times the final concentration in a 384-well plate. Then use Echo550 to transfer 250nl to a 384 reaction plate for storage. Add 250nl of 100% DMSO to the negative control well and positive control well, respectively.
[0306] (3) Prepare a kinase solution with a final concentration of 2.5 times using 1x kinase buffer. (4) Add 10 μL of a kinase solution having a final concentration of 2.5 times to each of the compound wells and the positive control wells, and add 10 μL of 1× Kinase buffer to the negative control wells.
[0307] (5) Centrifuge at 1,000 rpm for 30 seconds, shake to mix evenly, and then incubate at room temperature for 10 minutes. (6) Prepare a mixed solution of ATP and Kinase Substrate 2 at a final concentration of 25 / 15 using 1x Kinase buffer.
[0308] (7) Add 15 μL of a mixed solution of ATP and substrate at a final concentration of 25 / 15 to initiate the reaction. (8) Centrifuge the 384-well plate at 1,000 rpm for 30 seconds, shake to mix evenly, and then incubate at room temperature for 30 minutes.
[0309] (9) Add 30 μL of stop detection solution to stop the kinase reaction, centrifuge at 1000 rpm for 30 seconds, and shake to mix evenly. (10) Read the conversion rate using Caliper EZ Reader II.
[0310] 2. Data Analysis calculation formula
number
[0311] Biological Test Example 2: In vitro Reproduction Inhibition Experiment of MV4;11: Test materials: MV4;11 cell line was purchased from the Cell Bank of the Chinese Academy of Sciences and was supplemented with IMDM medium (Gibco, catalog no. 12440), fetal bovine serum (Gibco, catalog no. 10099141C), penicillin-streptomycin double antibody (Gibco, catalog no. 15140122), DMSO (Sigma, catalog no. D2650), Celltiter-Glo detection kit (CTG) (Promega, catalog no. G7573), 384-well clear flat-bottom black-walled cell culture plates (Corning, catalog no. 3764), D300e TLC instrument (Tecan, catalog no. D300e), and SpectraMax i3x microplate reader (MOLECULAR DEVICES, catalog no. i3x).
[0312] Testing Method: Cell culture: The MV4;11 cell culture conditions were IMDM, 10% fetal bovine serum, 1% penicillin-streptomycin double antibody, the cell density did not exceed 1.0 x 10E6 cells / mL, they were always in logarithmic growth phase, and the cell viability was more than 95%.
[0313] Preparation of compounds: Starting at 10 uM, test compounds are diluted 3-fold in DMSO for a total of nine concentrations. 60 nl of diluted compounds are added to cell culture plates to set up three duplicate well experiments.
[0314] Compound-treated cells: The prepared MV4;11 cell suspension is added to a 384-well plate, with 20 μL of cell suspension per well, i.e., 2000 MV4;11 cells per well, and a final DMSO concentration of 0.3%. The cell culture plate is placed in a 37° C., 5% carbon dioxide incubator for 72 hours. Add 20 μL of Promega CellTiter-Glo reagent per well to the cell culture plate and incubate with shaking at room temperature for 10 minutes to stabilize the luminescent signal. Read using a SpectraMax i3x microplate reader.
[0315] Data Analysis: Raw data were converted to percent inhibition and compound IC values were calculated by nonlinear four-parameter curve fitting. 50 The value (half inhibitory concentration) is obtained.
[0316] The following table records the test results in Biological Test Example 1 and Biological Test Example 2. The results show that the exemplary compounds of the present invention have strong inhibitory effect on FLT3 kinase and excellent inhibitory activity on MV4;11 cell proliferation. A:IC 5 0≦10nM, B: 10nM <IC 5 0≦100nM, C: 100nM <IC 5 0≦500nM, D:>500nM.
[0317] The activity test results of some compounds are shown in the following table. [Table 84-1] [Table 84-2] [Table 84-3] [Table 84-4] [Table 84-5] [Table 84-6] [Table 84-7]
[0318] All documents mentioned in the present invention are incorporated by reference in this application as if each document was incorporated by reference individually. Furthermore, after reading the above teachings of the present invention, those skilled in the art may make various changes or modifications to the present invention, and these equivalents are also included in the scope defined by the appended claims of this application.
Claims
1. A compound according to the following formula II, or a pharma- ceutically acceptable salt or deuterated form thereof: 【Chemistry 1】 where X and Y are N and Z is CR, where R is H, halogen, and substituted or unsubstituted C 1 -C 6 is a group selected from the group consisting of alkyl groups, Ra is H, substituted or unsubstituted C 1 -C 6 Alkyl group, substituted or unsubstituted C 2 -C 6 Alkenyl groups, and substituted or unsubstituted C 2 -C 6 alkynyl groups, U is a chemical bond or -NH-; Rc is a substituted or unsubstituted C 1 -C 6 Alkyl group, substituted or unsubstituted C 3 -C 8 a substituted or unsubstituted 3-8 membered heterocyclic ring containing 1-3 heteroatoms selected from carbocycle, oxygen, sulfur and nitrogen; a substituted or unsubstituted C 6 -C 10 selected from the group consisting of aryl groups, and substituted or unsubstituted 5-12 membered heteroaromatic rings containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen; Re is -NHR, R is H, substituted or unsubstituted C 1 -C 6 is a group selected from the group consisting of an alkyl group, a substituted or unsubstituted phenyl group, W is a substituted or unsubstituted C 6 -C 10 aryl groups, and substituted or unsubstituted 5-12 membered heteroaromatic rings containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen; The W group is substituted with at least one group having the structure -M-A, where M is a chemical bond, -CHR-, a carbonyl group, S, O, -NH-, -NHC(O)-, -NHS(O), 2 -, -NHC(O)NH-, -NHC(S)NH-, -COO-, and -O-S(O) 2 -, where R is a group selected from the group consisting of H, halogen, and substituted or unsubstituted C 1 -C 6 alkyl groups; The A is H, a halogen, a cyano group, an amino group, a nitro group, a hydroxyl group, a mercapto group, an aldehyde group, a carboxyl group, a sulfonyl group, a substituted or unsubstituted C 1 -C 6 Alkyl group, substituted or unsubstituted C 1 -C 6 Alkoxy groups, substituted or unsubstituted C 6 -C 10 an aryl group, a substituted or unsubstituted 4-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen; a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen; a substituted or unsubstituted -C 1 -C 6 Alkyl-phenyl group, substituted or unsubstituted C 3 -C 12 Cycloalkyl groups, substituted or unsubstituted C 2 -C 10 Acyl group, substituted or unsubstituted C 2 -C 10 Ester group, substituted or unsubstituted C 6 -C 10 Aryloxy groups, substituted or unsubstituted C 1 -C 6 Amide group, substituted or unsubstituted C 1 -C 4 Alkyl-S(O) 2 - and substituted or unsubstituted C 1 -C 4 alkyl-SO-; In the group A, the substitution refers to substitution with one or more groups selected from group B, and the group B is H, a halogen, ═O, a cyano group, an amino group, a nitro group, a hydroxyl group, a mercapto group, an aldehyde group, a carboxyl group, a sulfonyl group, a substituted or unsubstituted C 1 -C 6 Alkyl group, substituted or unsubstituted C 1 -C 6 Alkoxy groups, substituted or unsubstituted C 6 -C 10 an aryl group, a substituted or unsubstituted 3-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen; a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen; a substituted or unsubstituted -C 1 -C 6 Alkyl-phenyl group, substituted or unsubstituted C 3 -C 12 Cycloalkyl groups, substituted or unsubstituted C 2 -C 10 Acyl group, substituted or unsubstituted C 2 -C 10 Ester group, substituted or unsubstituted C 6 -C 10 Aryloxy groups, substituted or unsubstituted C 1 -C 6 Amide group, substituted or unsubstituted C 1 -C 4 Alkyl-S(O) 2 -, substituted or unsubstituted C 1 -C 4 In the group B, the substitution refers to substitution with one or more R groups, where R is H, a halogen, a cyano group, an amino group, a nitro group, a hydroxyl group, a mercapto group, an aldehyde group, a carboxyl group, a sulfonyl group, a substituted or unsubstituted C 1 -C 6 Alkyl group, substituted or unsubstituted C 1 -C 6 Alkoxy groups, substituted or unsubstituted C 6 -C 10 a substituted or unsubstituted 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from an aryl group, oxygen, sulfur and nitrogen; a substituted or unsubstituted -C 1 -C 6 Alkyl-phenyl group, substituted or unsubstituted C 3 -C 12 Cycloalkyl groups, substituted or unsubstituted C 2 -C 10 Acyl group, substituted or unsubstituted C 2 -C 10 Ester group, substituted or unsubstituted C 6 -C 10 Aryloxy groups, substituted or unsubstituted C 1 -C 6 Amide group, substituted or unsubstituted C 1 -C 4 Alkyl-S(O) 2 - and substituted or unsubstituted C 1 -C 4 is a group selected from the group consisting of alkyl-SO-, Unless otherwise specified, in each of the above formulas, the substitution means that the hydrogen atom of the corresponding group is replaced with deuterium, tritium, halogen, hydroxyl group, carboxyl group, mercapto group, benzyl group, C 1 -C 12 Alkoxycarbonyl group, C 1 -C 6 Aldehyde group, amino group, C 1 -C 6 Amido group, nitro group, cyano group, unsubstituted or halogenated C 1 -C 6 Alkyl group, unsubstituted or halogenated C 3 -C 8 Cycloalkyl group, C 2 -C 10 Alkenyl group, C 1 -C 6 Alkoxy group, C 1 -C 6 Alkyl-amine group, C 6 -C 10 Aryl group, 5- or 6-membered heteroaryl group, 5- or 6-membered non-aromatic heterocyclic group, —O—(C 6 -C 10 aryl), -O-(5- or 6-membered heteroaryl), C 1 -C 12 Alkylaminocarbonyl, unsubstituted or halogenated C 2 -C 10 Acyl groups, sulfonyl, phosphoryl, unsubstituted or halogenated C 1 -C 4 Alkyl-S(O) 2 - and unsubstituted or halogenated C 1 -C 4 The compound represented by formula II, or a pharma- ceutically acceptable salt or deuterated derivative thereof, characterized in that it is substituted with one or more substituents selected from the group consisting of alkyl-SO-.
2. The compound has the structure shown in formula IIa: 【Chemistry 2】 wherein the W ring is selected from the group consisting of a substituted or unsubstituted phenyl group, oxygen, and a substituted or unsubstituted 5-6 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur, and nitrogen, wherein the substitution in the W group refers to substitution with one or more groups selected from group A.
2. The compound of claim 1, or a pharma- ceutically acceptable salt or deuterated form thereof.
3. The W ring is a phenyl group. 【Chemistry 3】 A substituted or unsubstituted cyclic structure selected from the group consisting of 3. The compound of claim 2, or a pharma- ceutically acceptable salt or deuterated form thereof.
4. The W ring is a phenyl group. 【Chemistry 4】 A substituted or unsubstituted cyclic structure selected from the group consisting of 3. The compound of claim 2, or a pharma- ceutically acceptable salt or deuterated form thereof.
5. The compound has the structure shown in Formula III: 【Chemistry 5】 wherein the A ring is a substituted or unsubstituted 4-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C 6 -C 10 Aryl group, substituted or unsubstituted -C 1 -C 6 Alkyl-phenyl groups, and substituted or unsubstituted C 3 -C 12 cycloalkyl groups, M is a chemical bond, -O-, -CHR-, a carbonyl group, S, -NH-, -NHC(O)-, -NHS(O) 2 -, -NHC(O)NH-, -NHC(S)NH-, -COO-, and -O-S(O) 2 - characterized in that it is selected from the group consisting of 3. The compound of claim 2, or a pharma- ceutically acceptable salt or deuterated form thereof.
6. The compound has the structure shown in the formula: 【Chemistry 6】 Where: Rf is H, a halogen, a cyano group, an amino group, a nitro group, a hydroxyl group, a mercapto group, an aldehyde group, a carboxyl group, a sulfonyl group, C 1 -C 4 Alkyl-S(O) 2 -, substituted or unsubstituted C 1 -C 6 Alkyl groups, and substituted and unsubstituted C 1 -C 6 alkoxy groups; t is 0, 1, 2, 3 or 4; The A ring is selected from the group consisting of a substituted or unsubstituted 5-12 membered saturated ring, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, and a substituted or unsubstituted C 6 -C 10 aryl groups, and the A ring has at least one heteroatom selected from N or O.
6. The compound of claim 5, or a pharma- ceutically acceptable salt or deuterated form thereof.
7. The compound has the structure shown in the formula: 【Chemistry 7】 Where: Rf is H, a halogen, a cyano group, an amino group, a nitro group, a hydroxyl group, a mercapto group, an aldehyde group, a carboxyl group, a sulfonyl group, C 1 -C 4 Alkyl-S(O) 2 -, substituted or unsubstituted C 1 -C 6 Alkyl groups, and substituted or unsubstituted C 1 -C 6 alkoxy groups; t is 0, 1, 2, 3 or 4; L is N or CH; The A ring is a substituted or unsubstituted 4-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen; 3 -C 12 a cycloalkyl group, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, and a substituted or unsubstituted C 6 -C 10 aryl groups 6. The compound of claim 5, or a pharma- ceutically acceptable salt or deuterated form thereof.
8. The compound has the structure shown in Formula IV: 【Chemistry 8】 wherein the A ring is a substituted or unsubstituted 4-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C 6 -C 10 Aryl group, substituted or unsubstituted -C 1 -C 6 Alkyl-phenyl groups, and substituted or unsubstituted C 3 -C 12 cycloalkyl groups, M is a chemical bond, -O-, -CHR-, a carbonyl group, S, -NH-, -NHC(O)-, -NHS(O) 2 -, -NHC(O)NH-, -NHC(S)NH-, -COO-, and -O-S(O) 2 - selected from the group consisting of Ring B is a substituted or unsubstituted 4-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C 6 -C 10 Aryl groups, and substituted or unsubstituted C 3 -C 12 is selected from the group consisting of carbocycles; V is a chemical bond.
6. The compound of claim 5, or a pharma- ceutically acceptable salt or deuterated form thereof.
9. The A ring has at least one substituent G, and the G group is an amino group, a substituted or unsubstituted 4-7 membered heterocycle containing 1-3 heteroatoms selected from ═O, oxygen and nitrogen, a substituted or unsubstituted C 2 -C 10 Acyl group, substituted or unsubstituted C 2 -C 10 An ester group, and a substituted or unsubstituted C 1 -C 6 amide groups.
6. The compound of claim 5, or a pharma- ceutically acceptable salt or deuterated form thereof.
10. The compound is the following compound: 【Chemistry 9】 【Chemistry 10】 【Chemistry 11】 【Chemistry 12】 【Chemistry 13】 【Chemistry 14】 【Chemistry 15】 【Chemistry 16】 【Chemistry 17】 【Chemistry 18】 【Chemistry 19】 【Chemistry 20】 【Chemistry 21】 【Chemical 22】 【Chemistry 23】 【Chemistry 24】 【Chemistry 25】 【Chemistry 26】 【Chemical 27】 characterized in that it is selected from 2. The compound of claim 1, or a pharma- ceutically acceptable salt or deuterated form thereof.
11. A compound of formula IV, or a pharma- ceutically acceptable salt or deuterated form thereof, 【Chemistry 28】 wherein X and Y are N and Z is CR, where R is a group selected from the group consisting of H, halogen, and substituted or unsubstituted C 1 -C 6 alkyl groups; Ra is selected from the group consisting of H, a substituted or unsubstituted C 1 -C 6 alkyl group, a substituted or unsubstituted C 2 -C 6 alkenyl group, and a substituted or unsubstituted C 2 -C 6 alkynyl group; U is a chemical bond or -NH-; Rc is selected from the group consisting of a substituted or unsubstituted C 1 -C 6 alkyl group, a substituted or unsubstituted C 3 -C 8 carbocycle, a substituted or unsubstituted 3-8 membered heterocycle containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C 6 -C 10 aryl group, and a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen; Re is -NHR, where R is a group selected from the group consisting of H, a substituted or unsubstituted C 1 -C 6 alkyl group, and a substituted or unsubstituted phenyl group; The A ring is a substituted or unsubstituted 4-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C 6 -C 10 Aryl group, substituted or unsubstituted -C 1 -C 6 Alkyl-phenyl groups, and substituted or unsubstituted C 3 -C 12 cycloalkyl groups, M is a chemical bond, -O-, -CHR-, a carbonyl group, S, -NH-, -NHC(O)-, -NHS(O) 2 -, -NHC(O)NH-, -NHC(S)NH-, -COO-, and -O-S(O) 2 - selected from the group consisting of Ring B is a substituted or unsubstituted 4-12 membered heterocyclic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted 5-12 membered heteroaromatic ring containing 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, a substituted or unsubstituted C 6 -C 10 Aryl groups, and substituted or unsubstituted C 3 -C 12 is selected from the group consisting of carbocycles; V is -O-, -CHR-, a carbonyl group, S, -NH-, -NHC(O)-, -NHS(O) 2 -, -NHC(O)NH-, -NHC(S)NH-, -COO-, -OS(O) 2 or a pharma- ceutically acceptable salt or deuterated form thereof, characterized in that the compound of formula IV is selected from the group consisting of
12. below: 【Chemical Formula 29】 A compound, or a pharma- ceutically acceptable salt or deuterated form thereof, characterized in that it is selected from the group consisting of:
13. 1. A pharmaceutical composition comprising: The pharmaceutical composition comprises a therapeutically effective amount of one or more of the compounds according to any one of claims 1 to 12, their pharma- ceutically acceptable salts, racemates, R- and S-isomers, stereoisomers or tautomers, and one or more pharma- ceutically acceptable carriers, excipients, adjuvants, auxiliary agents and / or diluents.
14. Use of the compound according to any one of claims 1 to 12, a pharma- ceutically acceptable salt thereof, a racemate, an R-isomer, an S-isomer or a pharma- ceutically acceptable salt thereof in the preparation of a medicament for treating or preventing a disease associated with abnormalities in the gene level or abnormal expression of a kinase selected from the group consisting of FLT3, ALK, RET, ROS, AXL, and EGFR.
15. The above diseases include acute myeloid leukemia, type I neurofibroma, multiple myeloma, malignant glioma, non-small cell lung cancer, liver cancer, hepatocellular carcinoma, cervical cancer, lymphoma, bone metastasis cancer, hormone refractory prostate cancer, hormone dependent prostate cancer, thyroid tumor, medullary thyroid cancer, mesothelioma, glioblastoma, bone metastasis cancer, Merkel cell carcinoma, urogenital tumor, Merkel cell carcinoma, bladder cancer, papillary thyroid cancer, breast cancer, soft tissue sarcoma, glioma, neuroendocrine tumor, renal cell carcinoma, advanced solid tumor, undifferentiated The present invention relates to a method for treating a cancer of the present invention, the method comprising the steps of: (a) administering to a patient a cancer of the present invention, the method comprising ...
15. The use according to claim 14.
Citation Information
Patent Citations
Compounds and compositions as protein kinase inhibitors
JP2007522241A
antifibrotic pyridinone
JP2016500661A
antifibrotic pyridinone
JP2017512784A
Novel naphthyridines and isoquinolines and their use as CDK8 / 19 inhibitors
JP2017522324A
Substituted mono- and polyazanaphthalene derivatives and uses thereof
JP2018505207A
